1. A method of treating a neurological or an inflammatory condition comprising administering a therapeutically effective amount of a compound or pharmaceutically acceptable salt of the compound, wherein the compound has the structure of Formula (I):

wherein:

R² is selected from the group consisting of alkyl, haloalkyl, and cycloalkyl;

R⁴ is selected from the group consisting of H, halo, and alkoxy, wherein the alkoxy may be optionally substituted with one or more substituents independently selected from the group consisting of alkyl and halo, and wherein R⁴ is not methyl; and

R⁵ is selected from the group consisting of alkyl, haloalkyl, and cycloalkyl.

2. The method of claim 1 wherein each of R² and R⁵ has between one and five carbons.

3. The method of claim 1 wherein the condition is epilepsy, seizures, or convulsions.

4. The method of claim 1 wherein the condition is neuropathic pain or fibromyalgia. 5. The method of claim 1 wherein the condition is a psychological disorder.

6. The method of claim 5 wherein the psychological disorder is anxiety, mania, bipolar disorder, or depression. 7. The method of claim 1 , wherein the condition is Alzheimer's Disease, Huntington's Disease, Multiple Sclerosis, Parkinson's disease, Tourette's Syndrome, tinnitus, and tremors.

8. The method of Claims 1 or 3, wherein:

R² is selected from the group consisting of alkyl, haloalkyl, and cycloalkyl;

R⁴ is halo.

9. The method of Claim 8, wherein:

R⁴ is selected from the group consisting of Br, CI, and F.

10. The method of Claim 9, wherein:

R² is alkyl; and

R⁵ is alkyl having two or more carbons.

1 1 . The method of Claim 10, wherein the compound is selected from a group consisting of: 4- chloro-5-tert-butyl-2 -methyl-phenol; 4-chloro-2-isopropyl-5-methyl-phenol; 4-fluoro-2-iso propyl- 5 -methyl-phenol; 4-chloro-2,5-diisopropyl-phenol; 4-bromo-5-isopropyl-2-methylphenol; 4-bromo- 2-isopropyl-5 -methyl-phenol; 4-bromo-2-ieri-butyl-5 -isopropyl-phenol; 4-bromo-5 -tert-butyl-2- methyl-phenol; and 4-fluoro-5-tert-butyl-2-methyl-phenol.

12. The method of Claim 1, wherein the compound has the structure of Formula (II):

wherein:

R² is selected from the group consisting of alkyl, haloalkyl, and cycloalkyl;

R⁴ is selected from the group consisting of Br, CI, and F; and

R⁸, R⁹ and R¹⁰ are each independently selected from the group consisting of H, alkyl, and haloalkyl.

13. The method of Claim 1, wherein the compound has the structure of Formula (III)

wherein:

R² is selected from the group consisting of alkyl, haloalkyl, and cycloalkyl;

R⁵ is selected from the group consisting of alkyl, haloalkyl, and cycloalkyl; and

R₇ is selected from the group consisting of alkyl and haloalkyl.

14. The method of Claim 13, wherein:

R² is selected from the group consisting of alkyl, haloalkyl, and cycloalkyl;

R⁵ is selected from the group consisting of alkyl, haloalkyl, and cycloalkyl; and R7 is alkyl.

15. The method of Claim 14, wherein the compound has the structure of Formula (IV) :

wherein:

R² is selected from the group consisting of alkyl, haloalkyl, and cycloalkyl; and R⁵ is selected from the group consisting of alkyl, haloalkyl, and cycloalkyl.

16. The method of Claim 15, wherein:

R² is selected from the group consisting of alkyl and cycloalkyl; and

R⁵ is selected from the group consisting of alkyl and cycloalkyl.

17. A compound selected from the group consisting of: 4-bromo-5-ethyl-2-methyl-phenol; 4- fiuoro-5-isopropyl-2 -methyl-phenol; 4-bromo-5-tert-butyl-2 -methyl-phenol; 4-bromo-5- cyclopropyl-2-methyl-phenol; 4-bromo-2-ethyl-5-isopropyl-phenol; 4-chloro-2-ethyl-5-isopropyl- phenol; 2-ethyl-4-fluoro-5-isopropyl phenol; 4-bromo-5-isopropyl-2-propyl-phenol, 5-isopropyl-2- propyl-phenol; and 4-bromo-2,5-isopropyl-phenol.

18. A compound selected from the group consisting of: 4-bromo-2-methyl-5-(2,2,2-trifluoro-l- methyl-ethyl)-phenol; 4-bromo-5 -(2-fiuoro- 1 -methyl-ethyl)-2 -methyl-phenol; 4-bromo-2-methyl-5 - (2,2,2-trifluoro- l-trifiuoromethyl-ethyl)-phenol; 4-bromo-2-trifluoromethyl-5-(2,2,2-trifluoro-l- methyl-ethyl)-phenol; 4-bromo-2-cyclopropyl-5-isopropyl-phenol; 4-bromo-2,5-dicyclopropyl- phenol; 5-isopropyl-2-methyl-4-trifluoromethoxy-phenol; 2-cyclopropyl-5-isopropyl-4- trifluoromethoxy-phenol; 5-cyclopropyl-2-methyl-4-trifluoromethoxy-phenol; 2,5-dicyclopropyl-4- trifluoromethoxy-phenol; 4-tert-butoxy-5 -cyclopropyl-2-methyl-phenol; 4-tert-butoxy-2- cyclopropyl-5-methyl-phenol; 4-tert-butoxy-2,5-dicyclopropyl-phenol; 4-isopropoxy-5-isopropyl-2- methyl-phenol; 4-bromo-5-isopropyl-2-trifiuoromethyl-phenol; 4-bromo-5-(2-fluoro-l-methyl- ethyl)-2-methyl-phenol; and 4-tert-butoxy-5 -isopropyl-2-methyl-phenol.

19. A compound or pharmaceutically acceptable salt of the compound, wherein the compound has the structure of Formula (V):

wherein:

R is selected from the group consisting of haloalkyl and cycloalkyl; and

R⁵ is selected from the group consisting of haloalkyl and cycloalkyl. 20 A compound of Claim 19, wherein:

R is selected from the group consisting of trifluoroalkyl and cycloalkyl

R⁵ is selected from the group consisting of trifluoroalkyl and cycloalkyl.

21. A compound selected from the group consisting of: 5-(l ,2-dimethyl-propyl)-2-methyl-phenol; 5 -isobutyl-2-methyl-phenol; 5 -cyclopentyl-2 -methyl-phenol; 5 -sec-butyl-2-ethyl-phenol; 5-butyl-2- propyl-phenol; 5-isopropyl-2-propyl-phenol; 5-sec-butyl-2-propyl-phenol; 5tert -butyl-2-propyl- phenol; 2-butyl-5-isopropyl-phenol; 2 -butyl-5 -sec -butyl-phenol; 5-(tert-butyl)-2-butylphenol; 2- isopropyl-5 -propyl-phenol; 5-sec-butyl-2-isopropyl-phenol; 2-sec-butyl-5-ethyl-phenol; 2-s-ec-butyl- 5 -propyl-phenol; 5-butyl-2 -sec-butyl-phenol; 2-sec-butyl-5-isopropyl-phenol; 5-sec-butyl-2-tert- butyl-phenol; 2-methyl-5 -(2,2,2-trifluoro- 1 -methyl-ethyl)-phenol; 5 -(2-fluoro- 1 -methyl-ethyl)-2- methyl-phenol; 2-methyl-5-(2,2,2-trifluoro-l-trifluoromethyl-ethyl)-phenol; 2-trifluoromethyl-5- (2,2,2-trifiuoro- 1 -methyl-ethyl)-phenol; 5 -isopropyl-2-( 1 -methyl-butyl)-phenol; 2-isopropyl-5 - isopropyl-phenol; 2-cyclopropyl-5-isopropyl-phenol; and 2,5-dicyclopropyl-phenol.

22. A compound or pharmaceutically acceptable salt of the compound, wherein the compound has the structure of Formula (I):

wherein:

R is selected from the group consisting of methyl, cycloalkyl, and -CF₃;

R⁴ is halo;

R⁵ is selected from the group consisting of fluoroalkyl and a three, four, or five carbon cycloalkyl.

23. The compound of Claim 22, wherein:

R⁴ is selected from the group consisting of Br, CI, and F.

24. A compound or pharmaceutically acceptable salt of the compound, wherein the compound has the structure of Formula (III):

wherein:

R² and R^s are each independently selected from the group consisting of alkyl and cycloalkyl, wherein at least one of R² and R⁵ is cycloalkyl; and

R7 is selected from the group consisting of isopropyl, tert-butyl, and haloalkyl.

25. A compound of Claim 24, wherein:

R7 is selected from the group consisting of isopropyl and tert-butyl.

26. A compound or pharmaceutically acceptable salt of the compound of Claim 22, wherein the compound has the structure of Formula (IV):

(IV)

wherein:

R is selected from the group consisting of alkyl, and cycloalkyl; and

R⁵ is selected from the group consisting of alkyl, and cycloalkyl.

27. A method of treating epilepsy, seizures, or convulsions, the method comprising administering a therapeutically effective amount of a compound or of a pharmaceutically acceptable salt of the compound, wherein the compound has the structure of Formula (I):

wherein:

R² and R⁵ are each independently selected from the group consisting of methyl, isopropyl, and tert-butyl; and

R⁴ is selected from the group consisting of Br, CI, and F.

28. The method of any one of Claims 1-16 or 27, wherein the compound is deuterated. 29. The compound or pharmaceutically acceptable salt of any one of Claims 17-26, wherein the compound is deuterated.

30. A method of treating a neurological or an inflammatory condition comprising administering a therapeutically effective amount of a compound or pharmaceutically acceptable salt of the compound, wherein the compound has a structure of Formula (V):

wherein:

R is selected from the group consisting of an ester, a carbonate, a phosphate, a carbamate, a sulfamate, and an acylmethylester;

R² is selected from the group consisting of alkyl, haloalkyl, and cycloalkyl; R is selected from the group consisting of H, halo, and alkoxy, wherein the alkoxy may be optionally substituted with one or more substituents independently selected from the group consisting of alkyl and halo, and wherein R⁴ is not methyl; and

R⁵ is selected from the group consisting of alkyl, haloalkyl, and cycloalkyl.

31. The method of Claim 30, wherein the compound has a structure of Formula (VI):

wherein D¹ is alkyl, aryl, cycloalkyl, heterocycloalkyl, heteroalkyl, heteroaryl, heteroaralkyl, carbonylalkyl, or phosphonooxyalkyl, optionally substituted with one or more substituents selected from the group consisting of alkyl, carboxylate, heteroalkyl, monocyclic ring, bicyclic ring, and hydroxyl moieties.

The method of Claim 31 , wherein the compound has a structure of Formula (VII)

wherein:

D² and D³ together with the carbon atom to which they are bonded form a cycloalkyl or cycloheteroalkyl ring, or alternatively D² and D³ are each independently selected from the group consisting of hydrogen, alkyl, and heteroalkyl,;

A, Y, and one of D² or D³ together with the atoms to which they are bonded to form a cycloheteroalkyl ring, or alternatively A is selected from the group consisting of hydrogen, phosphono, alkyl, aryl, arylalkyl, heteroalkyl, heteroaryl, and heteroarylalkyl;

X is selected from the group consisting of— ND⁴— ,— O— ,— CH₂— , and— S— ; Y is selected from the group consisting of— O— and— ND— ;

n is an integer from 1 to 5; and

D⁴ is selected from the group consisting of hydrogen, alkyl, and arylalkyl.

33. The method of Claim 32, wherein D² and D³ are each hydrogen, X is— CI¾— , Y is— O— , A is phosphono, and n=l .

34. The method of Claim 30, wherein R¹ is selected from the group consisting of -P- 5

-CH₂-0-P-(0)(OD⁵)₂, -(CH₂)₂-0-P-(0)(OD⁵)₂, and -CH₂-0-P-(0)(OD³)₂, and further wherein D⁵ is H or a pharmaceutically acceptable cation.

35. The method of Claim 34, wherein the pharmaceutically acceptable cation is selected from the group consisting of Li⁺, Na⁺, and K⁺.

36. The method of Claim 30, wherein R¹ is selected from the group consisting of

37. The method of Claim 30, wherein R¹ is selected from the group consisting of

The method of Claim 30, wherein R is

39. The method of any one of the previous claims wherein:

alkyl is selected from the group consisting of methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, sec -butyl, pentanyl, isopentanyl, and neopentanyl;

haloalkyl is selected from the group consisting of nuoromethyl, 1 -fluoroethyl, 2-fluoroethyl, 1- fluoropropyl, 2-huoropropyl, 3-fluoropropyl, chloromethyl, 1 -chloro ethyl, 2-chloroethyl, 1- chloropropyl, 2-chloropropyl, 3-chloropropyl, bromomethyl, l-bromoethyl, 2-bromoethyl, 1- bromopropyl, 2-bromopropyl, and 3-bromopropyl; and cycloalkyl is selected from the group consisting of cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.

40. A method of treating a neurological or an inflammatory condition comprising administering a therapeutically effective amount of a compound or pharmaceutically acceptable salt of the compound, wherein the compound has a structure of Formula (I):

wherein:

R² is selected from the group consisting of alkyl, haloalkyl, and cycloalkyl, wherein the alkyl or haloalkyl is optionally substituted with one or more cycloalkykl substituents;

R⁴ is selected from the group consisting of alkyl, haloalkyl, and cycloalkyl, wherein the alkyl or haloalkyl is optionally substituted with one or more cycloalkykl substituents, and wherein R⁴ is not methyl; and

R⁵ is selected from the group consisting of alkyl, haloalkyl, and cycloalkyl.

41. The method of Claim 40 wherein each of R², R⁴, and R⁵ has between one and five carbons.

42. The method of Claim 41 wherein the condition is epilepsy, seizures, or convulsions.

43. The method of Claim 40 wherein the condition is neuropathic pain or fibromyalgia.

44. The method of Claim 40 wherein the condition is a psychological disorder. 45. The method of Claim 44 wherein the psychological disorder is anxiety, mania, bipolar disorder, or depression.

46. The method of Claim 40, wherein the condition is Alzheimer's Disease, Huntington's Disease, Multiple Sclerosis, Parkinson's disease, Tourette's Syndrome, tinnitus, and tremors.

The method of Claim 40, wherein the compound has a structure of Formula (II):

wherein:

Pv² is selected from the group consisting of alkyl, haloalkyl, and cycloalkyl;

Pv⁸ and R⁹ form a cycloalkyl of 1 , 2, 3, 4, 5, 6, 7, 8, 9, 10, 1 1 , 12, 13, or 14 carbons or R⁸ and R⁹ are each independently selected from the group consisting of H, alkyl, and haloalkyl;

R¹⁰ is selected from the group consisting of H, alkyl, and haloalkyl;

R¹² and R¹³ form a cycloalkyl of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 1 1 , 12, 13, or 14 carbons or R¹² and R¹³ are each independently selected from the group consisting of H, alkyl, and haloalkyl; and R¹⁴ is selected from the group consisting of H, alkyl, and haloalkyl.

48. The method of Claim 47, wherein halo is chloro, bromo, or fruoro.

49. The method of Claim 48, wherein the halo is fluoro.

50. The method of Claim 40, wherein the compound has a

structure of Formula (III) :

wherein:

R⁵ is selected from the group consisting of alkyl, haloalkyl, and cycloalkyl;

R¹² and R¹³ form a cycloalkyl of I, 2, 3, 4, 5, 6, 7, 8, 9, 10, 1 1 , 12, 13. or 14 carbons or R¹² and R¹³ are each independently selected from the group consisting of H, alkyl, and haloalkyl; and R¹⁴ is selected from the group consisting of H, alkyl, and haloalkyl;

R¹⁵ and R¹⁶ form a cycloalkyl of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 1 1 , 12, 13, or 14 carbons or R¹⁵ and R¹⁶ are each independently selected from the group consisting of H, alkyl, and haloalkyl; and R¹⁷ is selected from the group consisting of H, alkyl, and haloalkyl.

51. The method of Claim 50, wherein halo is chloro, bromo, or fluoro.

52. The method of Claim 51 , wherein the halo is fluoro.

53. The method of Claim 47, wherein:

R¹² and R¹³ form a cycloalkyl moiety; and

R¹⁴ is selected from the group consisting of alkyl and haloalkyl.

54. The method of Claim 50, wherein:

R¹² and R¹³ form a cycloalkyl moiety;

R¹⁵ and R¹⁶ form a cycloalkyl moiety; and

R¹⁴ and R¹⁷ are each independently selected from the group consisting of alkyl and haloalkyl.

55. The method of Claim 42, wherein:

R⁵ is selected from the group consisting of methyl and isopropyl;

R¹² is selected from the group consisting of H, halo, methyl, and cycloalkyl comprising R¹³; R¹³ is selected from the group consisting of H, halo, methyl, trihalomethyl, and cycloalkyl comprising R¹²;

R¹⁴ is selected from the group consisting of halo, methyl, trihalomethyl and pentahaloethyl;

R¹⁵ is selected from the group consisting of H, methyl, and trihalomethyl.

R¹⁶ is selected from the group consisting of H and cycloalkyl comprising R¹⁷; and

R¹⁷ is selected from the group consisting of H, methyl, and cycloalkyl comprising R¹⁶.

56. The method of Claim 55 wherein the halo is chloro, bromo, or fluoro.

57. The method of Claim 56, wherein the halo is fluoro.

58. The method of Claim 57, wherein the compound is selected from the group consisting of: 5- isopropyl-2-methyl-4-trifluoromethyl-phenol; 2,5-diisopropyl-4-trifluoromethyl-phenol; 4-(l ,1- dinuoroethyl)-2-isopropyl-5-methyl-phenol; 2-isopropyl-5-methyl-4-trifluoromethyl-phenol; 2- isopropyl-5 -methyl-4-( 1 -methyl-cyclopropyl)-phenol; 2-isopropyl-5 -methyl-4-( 1 -trifluoro-methyl- cyclopropyl)-phenol; 2-isopropyl-5-methyl-4-(2,2,3,3,3-pentafluoro-propyl)-phenol; 2-isopropyl-5- methyl-4-pentafluoroethyl-phenol; 2-isopropyl-5-methyl-4-(2,2,2-trifluoro- 1 , 1 -dimethyl-ethyl)- phenol; 4-tert-butyl-5 -methyl-2-(2,2,2-trifluoro- 1 -methyl-ethyl)-phenol; 4-iert-butyl-5 -methyl-2-( 1 - methyl-cyclopropyl)-phenol; and 4-tert-butyl-5-methyl-2-(l-trifluoro-methyl-cyclopropyl)-phenol.

59. A compound or pharmaceutically acceptable salt of the compound, wherein the compound has a structure of Formula (III):

R⁵ is selected from the group consisting of methyl and isopropyl;

R¹² is selected from the group consisting of H, halo, methyl, and cycloalkyl comprising R¹³; R¹³ is selected from the group consisting of H, halo, methyl, trihalomethyl, and cycloalkyl comprising R ;

R¹⁴ is selected from the group consisting of halo, methyl, trihalomethyl and pentahaloethyl;

R¹⁵ is selected from the group consisting of H, methyl, and trihalomethyl.

R¹⁶ is selected from the group consisting of H and cycloalkyl comprising R¹⁷; and

R¹⁷ is selected from the group consisting of H, methyl, and cycloalkyl comprising R¹⁶.

60. A compound or pharmaceutically acceptable salt of the compound, wherein the compound is selected from the group consisting of the species of Table 1, except 4-tert-butyl-5-ethyl-2 -methyl- phenol.

61. The compound or pharmaceutically acceptable salt of Claim 60, wherein the compound is selected from the group consisting of 5-isopropyl-2-methyl-4-trifluoromethyl-phenol; 2,5- diisopropyl-4-trifluoromethyl-phenol; 4-(l, l-difluoroethyl)-2-isopropyl-5-methyl-phenol; 2- isopropyl-5 -methyl-4-trifluoromethyl-phenol; 2-isopropyl-5-methyl-4-( 1 -methyl-cyclopropyl)- phenol; 2-isopropyl-5-methyl-4-(l-trifluoro-methyl-cyclopropyl)-phenol; 2-isopropyl-5-methyl-4- (2,2,3,3, 3-pentafluoro-propyl)-phenol; 2-isopropyl-5-methyl-4-pentafluoroethyl-phenol; 2- isopropyl-5-methyl-4-(2,2,2-trifluoro-l,l-dimethyl-ethyl)-phenol; 4-tert-butyl-5-methyl-2-(2,2,2- trifluoro-l-methyl-ethyl)-phenol; 4-tert-butyl-5-methyl-2-(l-methyl-cyclopropyl)-phenol; and 4-tert-butyl-5-methyl-2-(l-trifluoro-methyl-cyclopropyl)-phenol.

62. The method of any one of Claims 40-58, wherein the compound is deuterated.

63. The compound or pharmaceutically acceptable salt of any one of Claims 59-61 , wherein the compound is deuterated.

64. A method of treating a neurological or an inflammatory condition comprising administering a therapeutically effective amount of a compound or pharmaceutically acceptable salt of the compound, wherein the compound has a structure of Formula (IV):

wherein:

R is selected from the group consisting of an ester, a carbonate, a phosphate, a carbamate, a sulfamate, and an acylmethylester; R is selected from the group consisting of alkyl, haloalkyl, and cycloalkyl, wherein the alkyl or haloalkyl is optionally substituted with one or more cycloalkykl substituents;

R⁴ is selected from the group consisting of alkyl, haloalkyl, and cycloalkyl, wherein the alkyl or haloalkyl is optionally substituted with one or more cycloalkykl substituents, and wherein R⁴ is not methyl; and

R⁵ is selected from the group consisting of alkyl, haloalkyl, and cycloalkyl.

The method of Claim 64, wherein the compound has a structure of Formula (V):

wherein D¹ is alkyl, aryl, cycloalkyl, heterocycloalkyl, heteroalkyl, heteroaryl, heteroaralkyl, carbonylalkyl, or phosphonooxyalkyl, optionally substituted with one or more substituents selected from the group consisting of alkyl, carboxylate, heteroalkyl, monocyclic ring, bicyclic ring, and hydroxyl moieties.

66. The method of Claim 65, wherein the

compound has a structure of Formula (VI):

wherein:

D² and D³ together with the carbon atom to which they are bonded form a cycloalkyl or cycloheteroalkyl ring, or alternatively D² and D³ are each independently selected from the group consisting of hydrogen, alkyl, and heteroalkyl,;

A, Y, and one of D² or D³ together with the atoms to which they are bonded to form a cycloheteroalkyl ring, or alternatively A is selected from the group consisting of hydrogen, phosphono, alkyl, aryl, arylalkyl, heteroalkyl, heteroaryl, and heteroarylalkyl;

X is selected from the group consisting of— ND⁴— ,— O— ,— CH₂— , and— S— ;

Y is selected from the group consisting of— O— and— ND⁴— ;

n is an integer from 1 to 5; and

D⁴ is selected from the group consisting of hydrogen, alkyl, and arylalkyl.

67. The method of Claim 66, wherein D² and D³ are each hydrogen, X is— CH₂— , Y is— O— , A is phosphono, and n=l .

68. The method of Claim 64, wherein R¹ is selected from the group consisting of -P-(0)(OD⁵)₂,

CH₃

-CH₂-0-P-(0)(OD⁵)₂, -(CH₂)₂-0-P-(0)(OD⁵)₂, and -CH₂-0-P-(0)(OD⁵)₂, and further wherein D⁵ is H or a pharmaceutically acceptable cation.

69. The method of Claim 68, wherein the pharmaceutically acceptable cation is selected from the group consisting of Li⁺, Na⁺, and K⁺.

40. The method of Claim 64, wherein R¹ is selected from the group consisting of

The method of Claim 64, wherein R

72. The method of any one of the previous claims wherein:

alkyl is selected from the group consisting of methyl, ethyl, propyl, isopropyl, butyl, isobutyl, teri-butyl, sec-butyl, pentanyl, isopentanyl, and neopentanyl;

haloalkyl is selected from the group consisting of nuoromethyl, 1 -fluoroethyl, 2-fluoroethyl, 1- fluoropropyl, 2-huoropropyl, 3-fluoropropyl, chloromethyl, 1 -chloroethyl, 2-chloroethyl, 1- chloropropyl, 2-chloropropyl, 3-chloropropyl, bromomethyl, l-bromoethyl, 2-bromoethyl, 1- bromopropyl, 2-bromopropyl, and 3-bromopropyl; and

cycloalkyl is selected from the group consisting of cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.

73. A method of treating a neurological or an inflammatory condition comprising administering a therapeutically effective amount of a compound or pharmaceutically acceptable salt of the compound, wherein the compound has a structure of Formula (I):

wherein,

R² is selected from the group consisting of alkyl, haloalkyl, and cycloalkyl, wherein the alkyl or haloalkyl is optionally substituted with one or more cycloalkyl substituents;

R⁴ is selected from the group consisting of alkyl, haloalkyl, and cycloalkyl, wherein the alkyl or haloalkyl is optionally substituted with one or more cycloalkyl substituents, and wherein R⁴ is not methyl; and

R⁵ is selected from the group consisting of halo, and alkoxy, wherein the alkoxy may be optionally substituted with one or more substituents independently selected from the group consisting of alkyl and halo.

74. The method of Claim 73 wherein each of R², R⁴, and R⁵ has between one and five carbons.

75. The method of Claim 73 wherein the condition is epilepsy, seizures, or convulsions.

76. The method of Claim73 wherein the condition is neuropathic pain or fibromyalgia.

77. The method of Claim73 wherein the condition is a psychological disorder.

78. The method of Claim 77 wherein the psychological disorder is anxiety, mania, bipolar disorder, or depression.

79. The method of Claim 73, wherein the condition is Alzheimer's Disease, Huntington's Disease, Multiple Sclerosis, Parkinson's disease, Tourette's Syndrome, tinnitus, and tremors.

80. The method of Claim 74, wherein R² and R⁴ are not identical.

81. The method of Claim 74, wherein the compound has a structure of Formula (II):

R⁵ is halo;

R⁸ and R⁹ form a cycloalkyl of 1 , 2, 3, 4, 5, 6, 7, 8, 9, 10, 1 1 , 12, 13, or 14 carbons or R⁸ and R⁹ are each independently selected from the group consisting of H, alkyl, halo, and haloalkyl;

R¹⁰ is selected from the group consisting of H, alkyl, halo, and haloalkyl;

R¹² and R¹³ form a cycloalkyl of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 1 1 , 12, 13, or 14 carbons or R¹² and R¹³ are each independently selected from the group consisting of H, alkyl, halo, and haloalkyl; and

R¹⁴ is selected from the group consisting of H, alkyl, halo, and haloalkyl.

82. The method of Claim 80, wherein the compound has

structure of Formula (II)

wherein,

R⁵ is halo;

R⁸ and R⁹ form a cycloalkyl of 1 , 2, 3, 4, 5, 6, 7, 8, 9, 10, 1 1 , 12, 13, or 14 carbons or R⁸ and R⁹ are each independently selected from the group consisting of H, alkyl, halo, and haloalkyl;

R¹⁰ is selected from the group consisting of H, alkyl, halo, and haloalkyl;

R¹² and R¹³ form a cycloalkyl of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 1 1 , 12, 13, or 14 carbons or R¹² and R¹³ are each independently selected from the group consisting of H, alkyl, halo, and haloalkyl; and

R¹⁴ is selected from the group consisting of H, alkyl, halo, and haloalkyl.

83. The method of Claim 82, wherein halo is bromo, chloro, or fluoro.

The method of Claim 74, wherein the compound has a structure of Formula (III)

wherein,

R¹⁵ is selected from the group consisting of methyl, trihalomethyl, and isopropyl;

R⁸ and R⁹ form a cycloalkyl of 1 , 2, 3, 4, 5, 6, 7, 8, 9, 10, 1 1 , 12, 13, or 14 carbons or R⁸ and R⁹ are each independently selected from the group consisting of H, alkyl, halo, and haloalkyl;

R¹⁰ is selected from the group consisting of H, alkyl, halo, and haloalkyl;

R¹² and R¹³ form a cycloalkyl of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 1 1 , 12, 13, or 14 carbons or R¹² and R¹³ are each independently selected from the group consistmg of H, alkyl, halo, and haloalkyl; and

R¹⁴ is selected from the group consisting of H, alkyl, halo, and haloalkyl. The method of Claim 80, wherein the compound has a structure of Formula (III)

wherein,

R¹⁵ is selected from the group consisting of methyl, trihalomethyl, and isopropyl;

R⁸ and R⁹ form a cycloalkyl of 1 , 2, 3, 4, 5, 6, 7, 8, 9, 10, 1 1 , 12, 13, or 14 carbons or R⁸ and R⁹ are each independently selected from the group consisting of H, alkyl, halo, and haloalkyl;

R¹⁰ is selected from the group consisting of H, alkyl, halo, and haloalkyl;

R¹² and R¹³ form a cycloalkyl of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 1 1 , 12, 13, or 14 carbons or R¹² and R¹³ are each independently selected from the group consisting of H, alkyl, halo, and haloalkyl; and

R¹⁴ is selected from the group consisting of H, alkyl, halo, and haloalkyl.

The method of Claim 85, wherein halo is bromo, chloro, or fluoro.

87. The method of Claim 81 , wherein:

R¹² and R¹³ form a cycloalkyl moiety; and

R¹⁴ is selected from the group consisting of alkyl and haloalkyl.

88. The method of Claim 87, wherein:

R⁹ and R¹⁰ form a cycloalkyl moiety; and

R⁸ is selected from the group consisting of alkyl and haloalkyl. 89. The method of Claim 84, wherein:

R¹² and R¹³ form a cycloalkyl moiety; and

R¹⁴ is selected from the group consisting of alkyl and haloalkyl.

90. The method of Claim 89, wherein:

R⁹ and R¹⁰ form a cycloalkyl moiety; and

R⁸ is selected from the group consisting of alkyl and haloalkyl 91. A compound or pharmaceutically acceptable salt of the compound, wherein the compound is selected from the group consisting of the species of Table 1.

92. The method of Claim 75, wherein the compound is selected from the group consisting of 5- bromo-4-tert-butyl-2 -methyl-phenol, 5-bromo-4-tert-butyl-2-isopropyl-phenol, 4-tert-butyl-5- chloro-2-isopropyl-phenol, 4-tert-butyl-2-isopropyl-5 -trifluoromethoxy-phenol, 5 -bromo-2-(tert- butyl)-4-( 1 , 1 -dinuoroethyl)phenol, 5 -bromo-4-tert-butyl-2-cyclopropyl-phenol, 5 -bromo-2 - cyclopropyl-4-trifluoromethyl-phenol, 5-bromo-2-isopropyl-4-( 1 -trifluoromethyl-cyclopropyl)- phenol, 5-bromo-2-isopropyl-4-( 1 -methyl-cyclopropyl)-phenol, 5-bromo-2-isopropyl-4-(l - pentafluoroethyl-cyclopropyl)-phenol, 5 -bromo-2 -isopropyl-4-pentafluoroethyl-phenol, 5 -bromo-2 - isopropyl-4-(2,2,3,3,3-pentafmoro-propyl)-phenol, 5-bromo-2-isopropyl-4-(2,2,2-trifluoro-l ,l- dimethyl-ethyl)-phenol, 5-fluoro-2,4-bis-(l-methyl-cyclopropyl)-phenol, 5-bromo-4-(l-methyl- cyclopropyl)-2-( 1 -trifluoromethyl-cyclopropyl)-phenol, 5-fluoro-4-( 1 -methyl-cyclopropyl)-2- [ 1 - (2,2,2-trifluoro-ethyl)-cyclopropyl]-phenol, 2,4-bis-(l-methyl-cyclopropyl)-5-trifluoromethoxy- phenol, 2-[ 1 -(2,2,2 -Trifluoro-ethyl)-cyclopropyl]-5-trinuoromethoxy-4-( 1 -trifluoromethyl-cyclo- propyl)-phenol, 2-Isopropyl-5-trifluoromethoxy-4-(l-trifluoromethyl-cyclopropyl)-phenol, and 2- cyclopropyl-5-methoxy-4-(l-trifluoromethyl-cyclopropyl)-phenol.

93. The compound or pharmaceutically acceptable salt of Claim 91 , wherein the compound is selected from the group consisting of 5-bromo-4-tert-butyl-2 -methyl-phenol, 5-bromo-4-tert-butyl- 2-isopropyl-phenol, 4-tert-butyl-5-chloro-2-isopropyl-phenol, 4-tert-butyl-2-isopropyl-5-trifluoro- methoxy-phenol, 5-bromo-2-(tert-butyl)-4-(l, l-difluoroethyl)phenol, 5-bromo-4-tert-butyl-2- cyclopropyl-phenol, 5-bromo-2-cyclopropyl-4-trifluoromethyl-phenol, 5-bromo-2-isopropyl-4-(l- trifluoromethyl-cyclopropyl)-phenol, 5-bromo-2-isopropyl-4-(l-methyl-cyclopropyl)-phenol, 5- bromo-2-isopropyl-4-(l-pentafluoroethyl-cyclopropyl)-phenol, 5-bromo-2-isopropyl-4-pentafluoro- ethyl-phenol, 5-bromo-2-isopropyl-4-(2,2,3,3,3-pentafluoro-propyl)-phenol, 5-bromo-2-isopropyl-4- (2,2,2-trifluoro- 1 , 1 -dimethyl-ethyl)-phenol, 5-fluoro-2,4-bis-( 1 -methyl-cyclopropyl)-phenol, 5- bromo-4-(l-methyl-cyclopropyl)-2-(l-trifluoromethyl-cyclopropyl)-phenol, 5-fluoro-4-(l-methyl- cyclopropyl)-2-[ l -(2,2,2-trifluoro-ethyl)-cyclopropyl] -phenol, 2,4-bis-(l-methyl-cyclopropyl)-5- trifluoromethoxy-phenol, 2-[l-(2,2,2-Trifluoro-ethyl)-cyclopropyl]-5-trifluoromethoxy-4-(l-tri- fluoromethyl-cyclopropyl)-phenol, 2-Isopropyl-5-trifluoromethoxy-4-( 1 -trifluoromethyl-cyclo- propyl)-phenol, and 2-cyclopropyl-5-methoxy-4-(l-trifluoromethyl-cyclopropyl)-phenol.

94. The method of any one of Claims 73-90 or 92 wherein the compound is deuterated.

95. The compound or pharmaceutically acceptable salt of Claim 91 or 93, wherein the compound is deuterated.

96. A method of treating a neurological or an inflammatory condition comprising administering a therapeutically effective amount of a compound or pharmaceutically acceptable salt of the compound, wherein the compound has a structure of Formula (IV):

wherein:

R¹ is selected from the group consisting of an ester, a carbonate, a phosphate, a carbamate, a sulfamate, and an acylmethylester;

R² is selected from the group consisting of alkyl, haloalkyl, and cycloalkyl, wherein the alkyl or haloalkyl is optionally substituted with one or more cycloalkyl substituents;

R⁴ is selected from the group consisting of alkyl, haloalkyl, and cycloalkyl, wherein the alkyl or haloalkyl is optionally substituted with one or more cycloalkyl substituents, and wherein R⁴ is not methyl; and

R⁵ is selected from the group consisting of halo, and alkoxy, wherein the alkoxy may be optionally substituted with one or more substituents independently selected from the group consisting of alkyl and halo. The method of Claim 96, wherein the compound has a structure of Formula (V):

wherein D is alkyl, aryl, cycloalkyl, heterocycloalkyl, heteroalkyl, heteroaryl, heteroar alkyl, carbonylalkyl, or phosphonooxyalkyl, optionally substituted with one or more substituents selected from the group consisting of alkyl, carboxylate, heteroalkyl, monocyclic ring, bicyclic ring, and hydroxyl moieties.

The method of Claim 97, wherein the compound has a structure of Formula (VI)

wherein:

D² and D³ together with the carbon atom to which they are bonded form a cycloalkyl or cycloheteroalkyl ring, or alternatively D² and D³ are each independently selected from the group consisting of hydrogen, alkyl, and heteroalkyl,; A, Y, and one of D² or D³ together with the atoms to which they are bonded to form a cycloheteroalkyl ring, or alternatively A is selected from the group consisting of hydrogen, phosphono, alkyl, aryl, arylalkyl, heteroalkyl, heteroaryl, and heteroarylalkyl;

X is selected from the group consisting of— ND⁴— ,— O— ,— CH₂— , and— S— ;

Y is selected from the group consisting of— O— and— ND⁴— ;

n is an integer from 1 to 5; and

D⁴ is selected from the group consisting of hydrogen, alkyl, and arylalkyl.

99. The method of Claim 98, wherein D² and D³ are each hydrogen, X is— CH₂— , Y is— O— , A is phosphono, and n=l .

100. The method of Claim 96, wherein R¹ is selected from the group consisting of -P-(0)(OD⁵)₂,

CH₃

-CH₂-0-P-(0)(OD⁵)₂, -(CH₂)₂-0-P-(0)(OD⁵)₂, and -CH₂-0-P-(0)(OD⁵)₂, and further wherein D⁵ is H or a pharmaceutically acceptable cation.

101. The method of Claim 100, wherein the pharmaceutically acceptable cation is selected from the group consisting of Li⁺, Na⁺, and K⁺.

103. The method of Claim 96, wherein R¹ is selected from the group consisting of

104. The method of Claim 24, wherein R¹ is

105. The method of any one of the previous claims wherein:

alkyl is selected from the group consisting of methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, sec -butyl, pentanyl, isopentanyl, and neopentanyl;

haloalkyl is selected from the group consisting of nuoromethyl, 1 -nuoroethyl, 2-fluoroethyl, 1- fluoropropyl, 2-fluoropropyl, 3-fluoropropyl, chloromethyl, 1 -chloroethyl, 2-chloroethyl, 1- chloropropyl, 2-chloropropyl, 3-chloropropyl, bromomethyl, 1-bromoethyl, 2-bromoethyl, 1- bromopropyl, 2-bromopropyl, and 3-bromopropyl; and

cycloalkyl is selected from the group consisting of cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.

106. A method of treating a neurological or an inflammatory condition comprising administering a therapeutically effective amount of a compound or pharmaceutically acceptable salt of the compound, wherein the compound has a structure of Formula (I):

wherein:

R² is selected from the group consisting of alkyl, haloalkyl, and cycloalkyl, wherein the alkyl or haloalkyl is optionally substituted with one or more cycloalkykl substituents;

R⁴ is selected from the group consisting of H, halo, alkyl, alkoxy, haloalkyl, haloalkoxy and cycloalkyl, wherein alkyl or haloalkyl is optionally substituted with one or more cycloalkyl substituents, wherein alkoxy alkyl hydrogens may be optionally substituted with one or more substituents independently selected from the group consisting of alkyl and halo, and wherein R⁴ is not methyl;

R⁵ is selected from the group consisting of alkyl, haloalkyl, cycloalkyl, halo, and alkoxy, wherein the alkoxy may be optionally substituted with one or more substituents independently selected from the group consisting of alkyl and haloalkyl; and

R⁶ is halo.

107. The method of Claim 106, wherein each of R², R⁴, and R⁵ has between one and five carbons. 108. The method of Claim 106, wherein the condition is epilepsy, seizures, or convulsions. 109. The method of Claim 106, wherein the condition is neuropathic pain or fibromyalgia.

110. The method of Claim 106, wherein the condition is a psychological disorder.

111. The method of Claim 1 10, wherein the psychological disorder is anxiety, mania, bipolar disorder, or depression.

112. The method of Claim 106, wherein the condition is Alzheimer's Disease, Huntington's Disease, Multiple Sclerosis, Parkinson's disease, Tourette's Syndrome, tinnitus, and tremors.

113. The method of Claim 107, wherein R² and R⁴ are not identical.

114. The method of Claim 107, wherein the compound has a structure of Formula (II):

wherein:

R⁵ is halo;

R⁶ is halo;

R⁸, R⁹, and R¹⁰ are each independently selected from the group consisting of H, alkyl, halo, haloalkyl, cycloalkyl comprising R⁸ and R⁹, and cycloalkyl comprising R⁹ and R¹⁰; and

R¹², R¹³, and R¹⁴ are each independently selected from the group consisting of H, alkyl, halo, haloalkyl, cycloalkyl comprising R¹² and R¹³, and cycloalkyl comprising R¹³ and R¹⁴.

115. The method of Claim 113, wherein the compound has a structure of Formula (II), wherein:

R⁵ is halo;

R⁶ is halo;

R⁸, R⁹, and R¹⁰ are each independently selected from the group consisting of H, alkyl, halo, haloalkyl, cycloalkyl comprising R⁸ and R⁹, and cycloalkyl comprising R⁹ and R¹⁰; and

R¹², R¹³, and R¹⁴ are each independently selected from the group consisting of H, alkyl, halo, haloalkyl, cycloalkyl comprising R¹² and R¹³, and cycloalkyl comprising R¹³ and R¹⁴.

116. The method of Claim 114, wherein halo is Br, CI, or F.

117. The method of Claim 107, wherein the compound has a structure of Formula (III):

R⁶ is halo;

R⁸, R⁹, and R¹⁰ are each independently selected from the group consisting of H, alkyl, halo, haloalkyl, cycloalkyl comprising R⁸ and R⁹, and cycloalkyl comprising R⁹ and R¹⁰;

R¹², R¹³, and R¹⁴ are each independently selected from the group consisting of H, alkyl, halo, haloalkyl, cycloalkyl comprising R¹² and R¹³, and cycloalkyl comprising R¹³ and R¹⁴; and

R¹⁵ is selected from the group consisting of methyl, trihalomethyl, and isopropyl. 118. The method of Claim 113, wherein the compound has a structure of Formula (III) and wherein:

R¹⁵ is selected from the group consisting of methyl, trihalomethyl, and isopropyl;

R⁸, R⁹, and R¹⁰ are each independently selected from the group consisting of H, alkyl, halo, haloalkyl, cycloalkyl comprising R⁸ and R⁹, and cycloalkyl comprising R⁹ and R¹⁰; and

R¹², R¹³, and R¹⁴ are each independently selected from the group consisting of H, alkyl, halo, haloalkyl, cycloalkyl comprising R¹² and R¹³, and cycloalkyl comprising R¹³ and R¹⁴.

The method of Claim 117, wherein halo is bromo, chloro, or fluoro.

120. The method of Claim 114, wherein:

R¹² and R¹³ form a cycloalkyl moiety; and

R¹⁴ is selected from the group consisting of alkyl and haloalkyl.

121. The method of Claim 120, wherein:

R⁹ and R¹⁰ form a cycloalkyl moiety; and

R⁸ is selected from the group consisting of alkyl and haloalkyl.

The method of Claim 117, wherein:

R¹² and R¹³ form a cycloalkyl moiety; and

R¹⁴ is selected from the group consisting of alkyl and haloalkyl.

The method of Claim 122, wherein:

R⁹ and R¹⁰ form a cycloalkyl moiety; and

R⁸ is selected from the group consisting of alkyl and haloalkyl.

124. The method of Claim 108, wherein the compound is selected from the group consisting of the species of Table 1.

125. A compound or pharmaceutically acceptable salt of the compound, wherein the compound is selected from the group consisting of the species of Table 1.

The method of Claim 106, wherein the compound has a structure of Formula (IV):

wherein:

R² is selected from the group consisting of alkyl, haloalkyl, and cycloalkyl;

R⁶ is halo;

R⁸, R⁹, and R¹⁰ are each independently selected from the group consisting of H, alkyl, haloalkyl, cycloalkyl comprising R⁸ and R⁹, and cycloalkyl comprising R and R^llJ; and R , R , and R are each independently selected from the group consisting of H, alkyl, haloalkyl, cycloalkyl comprising R¹² and R¹³, and cycloalkyl comprising R¹³ and R¹⁴.

127. The method of Claim 126, wherein halo is chloro, bromo, or fluoro.

128. The method of Claim 127, wherein the halo is fluoro.

129. The method of Claim 106, wherein the compound has a structure of Formula (V):

R is selected from the group consisting of alkyl, haloalkyl, and cycloalkyl;

R⁶ is halo;

R¹² and R¹³ form a cycloalkyl of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 1 1 , 12, 13, or 14 carbons or R¹² and R¹³ are each independently selected from the group consisting of H, alkyl, and haloalkyl;

R¹⁴ is selected from the group consisting of H, alkyl, and haloalkyl;

R¹⁵ and R¹⁶ form a cycloalkyl of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 1 1 , 12, 13, or 14 carbons or R¹⁵ and R¹⁶ are each independently selected from the group consisting of H, alkyl, and haloalkyl; and R¹⁷ is selected from the group consisting of H, alkyl, and haloalkyl.

130. The method of Claim 129, wherein halo is chloro, bromo, or fluoro.

131. The method of Claim 130, wherein the halo is fluoro. 132. The method of Claim 126, wherein:

R¹² and R¹³ form a cycloalkyl moiety; and R is selected from the group consisting of alkyl and haloalkyl.

133. The method of Claim 129, wherein:

R¹² and R¹³ form a cycloalkyl moiety;

R¹⁵ and R¹⁶ form a cycloalkyl moiety; and

R¹⁴ and R¹⁷ are each independently selected from the group consisting of alkyl and haloalkyl.

134. The method of Claim 129, wherein the compound has a structure of Formula (V), and wherein:

R⁵ is selected from the group consisting of methyl and isopropyl;

R¹² is selected from the group consisting of H, halo, methyl, and cycloalkyl comprising R¹³; R¹³ is selected from the group consisting of H, halo, methyl, trihalomethyl, and cycloalkyl comprising R¹²;

R¹⁴ is selected from the group consisting of halo, methyl, trihalomethyl and pentahaloethyl;

R¹⁵ is selected from the group consisting of H. methyl, and trihalomethyl.

R¹⁶ is selected from the group consisting of H and cycloalkyl comprising R¹⁷; and

R¹⁷ is selected from the group consisting of H, methyl, and cycloalkyl comprising R¹⁶.

135. The method of Claim 134, wherein the halo is chloro, bromo, or fluoro.

136. The method of Claim 135, wherein the halo is fluoro.

137. The method of Claim 135, wherein the compound is selected from the group consisting of the species of Table 2.

138. A compound or pharmaceutically acceptable salt of the compound, wherein the compound has a structure of Formula (V)

wherein:

R⁵ is selected from the group consisting of methyl and isopropyl;

R¹² is selected from the group consisting of H, halo, methyl, and cycloalkyl comprising R¹³; R¹³ is selected from the group consisting of H, halo, methyl, trihalomethyl, and cycloalkyl comprising R¹²;

R¹⁴ is selected from the group consisting of halo, methyl, trihalomethyl and pentahaloethyl;

R¹⁵ is selected from the group consisting of H, methyl, and trihalomethyl.

R¹⁶ is selected from the group consisting of H and cycloalkyl comprising R¹⁷; and

R¹⁷ is selected from the group consisting of H, methyl, and cycloalkyl comprising R¹⁵.

139. The compound or pharmaceutically acceptable salt of Claim 138, wherein the compound is selected from the group consisting of the species of Table 2.

140. The method of Claim 106, wherein:

R² is selected from the group consisting of alkyl, haloalkyl, and cycloalkyl; and

R⁴ is halo.

141. The method of Claim 140, wherein:

R⁴ is selected from the group consisting of Br, CI, and F.

142. The method of Claim 141 , wherein:

R² is alkyl; and

R⁵ is alkyl having two or more carbons.

143. The method of Claim 142, wherein the compound is selected from the group consisting of 4- bromo-2-fluoro-3-isopropyl-6-methyl-phenol, 4-chloro-2-nuoro-3-isopropyl-6-methyl-phenol, 2,4- difluoro-3-isopropyl-6-methyl-phenol, 4-bromo-2-fluoro-3-isopropyl-6-trifluoromethyl-phenol, 4- bromo-2-fluoro-6-trifluoromethyl-3-(2,2,2-trifluoro- 1 -methyl-ethyl)-phenol, 4-bromo-6-cyclo propyl-2-fluoro-3-(2,2,2-trifluoro-l-methyl-ethyl)-phenol, 4-bromo-3-cyclopropyl-2-fluoro-6- methyl-phenol, 4-bromo-3-cyclopropyl-2-fluoro-6-trifluoromethyl-phenol, 4-bromo-3 ,6-dicyclo propyl-2-fluoro-phenol, 4-bromo-2-chloro-3-isopropyl-6-methyl-phenol, 2-fluoro-3-isopropyl-6- methyl-4-trifluoromethoxy-phenol, 2-bromo-3 -isopropyl-6-methyl-4-trifluoro-methoxy-phenol, 2- chloro-3 -isopropyl-6-methyl-4-trifluoromethoxy-phenol, 4-tert-butoxy-2-fluoro-3 -isopropyl-6- methyl-phenol, 2-bromo-4-tert-butoxy-3-isopropyl-6-methyl-phenol, 4-bromo-3-(2,2-difluoro-l- methyl-ethyl)-2-fluoro-6-isopropyl-phenol, 4-bromo-2-fluoro-6-iso-propyl-3-pentafluoroethyl- phenol, 4-bromo-2-fluoro-6-isopropyl-3-(2,2,2-trifluoro-ethyl)-phenol, 4-bromo-3-ethyl-2-fluoro-6- (2,2,2-trifluoro- 1 , 1 -dimethyl-ethyl)-phenol, 4-bromo-2-fluoro-6-isopropyl-3-(2,2,2-trifluoro- 1 - trifluoromethyl-ethyl)-phenol, 4-bromo-2-fluoro-6-iso-propyl-3-(2,2,3,3,3-pentafluoro-propyl)- phenol, 2-fluoro-6-isopropyl-3-(2,2,3,3,3-pentafluoro-propyl)-4-trifluoro-methoxy-phenol, 2-fluoro- 4-isopropoxy-6-isopropyl-3-(2,2,2-trifluoro-ethyl)-phenol, 2-fluoro-6-isopropyl-4-methoxy-3-(2,2,2- trifluoro-ethyl)-phenol, 3-ethyl-2-fluoro-6-(2,2,2-trifluoro- 1 , 1 -dimethyl-ethyl)-4-trifluoro methoxy- phenol, 2-fluoro-6-isopropyl-4-methoxy-3-(2,2,2-trifluoro-ethyl)-phenol, 4-tert-butoxy-3-(2,2- difluoro- 1 -methyl-ethyl)-2-fluoro-6-isopropyl-phenol, 2-bromo-3 -isopropyl-4-trifluorometh oxy-6- (2,2,2-trifluoro- 1 -methyl-ethyl)-phenol, 3 -ethyl-2-fluoro-6-(2,2,2-trifluoro-ethy)-4-triiluoro methoxy-phenol, 4-tert-butoxy-3-ethyl-2-fluoro-6-(2,2,2-trirluoro-ethyl)-phenol, and 3-ethyl-2- fluoro-4-isopropoxy-6-(2,2,2-trifluoro-ethyl)-phenol. 144. The method of Claim 108, wherein the compound is selected from the group consisting of 4- bromo-2-fluoro-3-isopropyl-6-methyl-phenol, 4-chloro-2-fluoro-3-isopropyl-6-methyl-phenol, 2,4- difluoro-3-isopropyl-6-methyl-phenol, 4-bromo-2-fluoro-3-isopropyl-6-trifluoromethyl-phenol, 4- bromo-2-fluoro-6-trifluoromethyl-3-(2,2,2-trifluoro- 1 -methyl-ethyl)-phenol, 4-bromo-6-cyclo propyl-2-fluoro-3-(2,2,2-trifluoro-l-methyl-ethyl)-phenol, 4-bromo-3-cyclopropyl-2-fLuoro-6- methyl-phenol, 4-bromo-3,6-dicyclopropyl-2-fluoro-phenol, 2,4-dibromo-3-isopropyl-6-methyl- phenol, 4-bromo-2-chloro-3-isopropyl-6-methyl-phenol, 2,4-dichloro-3-isopropyl-6-methyl-phenol, 2,4-dibromo-3-isopropyl-6-(2,2,2-trifiuoro- 1 -methyl-ethyl)-phenol, 4-bromo-3-(l , 1 -difluoroethyl)- 2-fluoro-6-isopropyl-phenol, 2-iluoro-6-isopropyl-3-(2,2,3,3₅3-pentafluoro-propyl)-4-trifluorometh oxy-phenol, 2-fluoro-4-isopropoxy-6-isopropyl-3-(2,2,2-trifluoroethyl)-phenol, 2-fluoro-6- isopropyl-4-methoxy-3-(2,2,2-trifiuoroethyl)-phenol, 4-tert-butoxy-3-ethyl-2-fluoro-6-(2,2,2-tri fluoroethyl)-phenol, 2-fluoro-3-isopropyl-6-methyl-4-trifluoromethoxy -phenol, 2-bromo-3- isopropyl-6-methyl-4-trifiuoromethoxy-phenol, and 2-chloro-3-isopropyl-6-methyl-4-trifiuoro methoxy-phenol.

145. The method of Claim 106, wherein the compound has the structure of Formula (VI):

wherein:

R² is selected from the group consisting of alkyl, haloalkyl, and cycloalkyl;

R⁴ is selected from the group consisting of Br, CI, and F;

R⁶ is halo; and

R⁸, R⁹ and R¹⁰ are each independently selected from the group consisting of H, alkyl, and haloalkyl.

146. The method of Claim 106, wherein the compound has the structure of Formula (VII):

wherein:

R² is selected from the group consisting of alkyl, haloalkyl, and cycloalkyl;

R⁵ is selected from the group consisting of alkyl, haloalkyl, and cycloalkyl;

R⁶ is halo; and

R7 is selected from the group consisting of alkyl and haloalkyl.

147. The method of Claim 145, wherein:

R² is selected from the group consisting of alkyl, haloalkyl, and cycloalkyl;

R⁵ is selected from the group consisting of alkyl, haloalkyl, and cycloalkyl; and

R7 is alkyl.

148. The method of Claim 146, wherein the compound has the structure of Formula (VIII):

wherein:

R² is selected from the group consisting of alkyl, haloalkyl, and cycloalkyl; and

R⁵ is selected from the group consisting of alkyl, haloalkyl, and cycloalkyl.

The method of Claim 148, wherein:

R² is selected from the group consisting of alkyl and cycloalkyl; and

R⁵ is selected from the group consisting of alkyl and cycloalkyl.

150. A compound or pharmaceutically acceptable salt of the compound, wherein the compound has the structure of Formula (X):

wherein:

R² is selected from the group consisting of methyl, cycloalkyl, and -CF₃;

R⁴ is halo;

R⁵ is selected from the group consisting of fluoroalkyl and a three, four, or five carbon cycloalkyl;

R⁶ is halo; and R and R are not both Br or both CI.

151. The compound or pharmaceutically acceptable salt of Claim 150, wherein:

R⁴ is selected from the group consisting of Br, CI, and F.

152. A compound or pharmaceutically acceptable salt of the compound, wherein the compound has

R² and R⁵ are each independently selected from the group consisting of alkyl and cycloalkyl, wherein at least one of R² and R⁵ is cycloalkyl;

R⁶ is halo; and

R₇ is selected from the group consisting of isopropyl, tert-butyl, and haloalkyl.

153. The compound or pharmaceutically acceptable salt of Claim 152, wherein:

R₇ is selected from the group consisting of isopropyl and tert-butyl.

154. The compound or pharmaceutically acceptable salt of Claim 152, wherein:

R² is selected from the group consisting of alkyl, and cycloalkyl;

R⁵ is selected from the group consisting of alkyl, and cycloalkyl; and

R⁷ is trifhioromethyl.

155. The method of Claim 109, wherein:

R² and R⁵ are each independently selected from the group consisting of methyl, isopropyl, and tert-butyl; and

R⁴ and R⁶ are each independently selected from the group consisting of Br, CI, and F.

156. The compound or pharmaceutically acceptable salt of Claim 151 , wherein the compound is selected from the group consisting of 4-bromo-2-fluoro-3-isopropyl-6-methyl-phenol, 4-chloro-2- fluoro-3-isopropyl-6-methyl-phenol, 2,4-difluoro-3-isopropyl-6-methyl-phenol, 4-bromo-2-fluoro-3- isopropyl-6-trifluoromethyl-phenol, 4-bromo-2-fluoro-6-trifiuoromethyl-3-(2,2,2-trifluoro-l-methyl- ethyl)-phenol, 4-bromo-6-cyclopropyl-2-fiuoro-3-(2,2,2-trifiuoro- 1 -methyl-ethyl)-phenol, 4-bromo-

3- cyclopropyl-2-fluoro-6-methyl-phenol, 4-bromo-3-cyclopropyl-2-iluoro-6-trifluoromethyl-phenol,

4- bromo-3,6-dicyclopropyl-2-fluoro-phenol, 4-bromo-2-chloro-3-isopropyl-6-methyl-phenol, 2- fluoro-3-isopropyl-6-methyl-4-trifluoromethoxy-phenol, 2-bromo-3-isopropyl-6-methyl-4- trifluoromethoxy-phenol, 2-chloro-3-isopropyl-6-methyl-4-trifluoromethoxy-phenol, 4-tert-butoxy- 2-fluoro-3-isopropyl-6-methyl-phenol, 2-bromo-4-tert-butoxy-3-isopropyl-6-methyl-phenol, 4- bromo-3-(2,2-difluoro-l-methyl-ethyl)-2-fluoro-6-isopropyl-phenol, 4-bromo-2-fluoro-6-iso-propyl- 3-pentafluoroethyl-phenol, 4-bromo-2-fluoro-6-isopropyl-3-(2,2,2-trifluoro-ethyl)-phenol, 4-bromo- 3-ethyl-2-fluoro-6-(2,2,2-trifluoro- l ,l-dimethyl-ethyl)-phenol, 4-bromo-2-fluoro-6-iso-propyl-3- (2,2,2-trifiuoro- 1 -trifiuoromethyl-ethyl)-phenol, 4-bromo-2-fluoro-6-isopropyl-3-(2,2,3 , 3 ,3- pentafluoro-propyl)-phenol, 2-fluoro-6-isopropyl-3-(2,2,3,3,3-pentafluoro-propyl)-4-trifluoro- methoxy-phenol, 2-fluoro-4-isopropoxy-6-isopropyl-3-(2,2,2-trifluoro-ethyl)-phenol, 2-fluoro-6- isopropyl-4-methoxy-3-(2,2,2-trifluoro-ethyl)-phenol, 3-ethyl-2-fiuoro-6-(2,2,2-frifluoro-l , l-di- methyl-ethyl)-4-trifiuoromethoxy-phenol, 2-fluoro-6-isopropyl-4-methoxy-3-(2,2,2-trifluoro-ethyl)- phenol, 4-tert-butoxy-3-(2,2-difluoro-l-methyl-ethyl)-2-fluoro-6-isopropyl-phenol, 2-bromo-3- isopropyl-4-trifiuoromethoxy-6-(2,2,2-trifluoro-l-methyl-ethyl)-phenol, 3-ethyl-2-fluoro-6-(2,2,2- trifluoro-ethyl)-4-trifluoromethoxy-phenol, 4-tert-butoxy-3-ethyl-2-iluoro-6-(2,2₅2-trifluoro-ethyl)- phenol, and 3-ethyl-2-fluoro-4-isopropoxy-6-(2,2,2-trifluoro-ethyl)-phenol.

157. The compound or pharmaceutically acceptable salt of Claim 156, wherein the compound is selected from the group consisting of 4-bromo-2-fluoro-3-isopropyl-6-methyl-phenol, 4-chloro-2- fluoro-3-isopropyl-6-methyl-phenol, 2,4-difluoro-3-isopropyl-6-methyl-phenol, 4-bromo-2-fluoro-3- isopropyl-6-trifluoromethyl-phenol, 4-bromo-2-fluoro-6-trifluoromethyl-3-(2,2,2-trifluoro-l-methyl- ethyl)-phenol, 4-bromo-6-cyclopropyl-2-fluoro-3-(2,2,2-trifluoro- 1 -methyl-ethyl)-phenol, 4-bromo- 3-cyclopropyl-2-fluoro-6-methyl-phenol, 4-bromo-3,6-dicyclopropyl-2-fluoro-phenol, 4-bromo-2- chloro-3-isopropyl-6-methyl-phenol, 2,4-dibromo-3-isopropyl-6-(2,2,2-trifluoro- 1 -methyl-ethyl)- phenol, 4-bromo-3-(l ,l-difluoroethyl)-2-fluoro-6-isopropyl-phenol, 2-fluoro-6-isopropyl-3- (2,2,3,3, 3-pentafluoro-propyl)-4-trifluoromethoxy-phenol, 2-fluoro-4-isopropoxy-6-isopropyl-3- (2,2,2-trifluoroethyl)-phenol, 2-fluoro-6-isopropyl-4-methoxy-3-(2,2,2-rrirluoroethyl)-phenol, 4-tert- butoxy-3-ethyl-2-fluoro-6-(2,2,2-trifluoro-ethyl)-phenol, 2-fi'uoro-3-isopropyl-6-methyl-4-trinuoro- methoxy-phenol, 2-bromo-3-isopropyl-6-methyl-4-trifluoromethoxy-phenol, and 2-chloro-3- isopropyl-6-methyl-4-trifluoromethoxy-phenol.

158. The method of Claim 108, wherein the compound is selected from the group consisting of 4- tert-butyl-2-fluoro-6-isopropyl-3-methyl-phenol, 4-tert-butyl-2-fluoro-6-isopropyl-3-trifluoromethyl- phenol, 2-fluoro-6-isopropyl-3-methyl-4-(2,2,2-trinuoro- 1 , 1 -dimethyl-ethyl)-phenol, 2-bromo-6- isopropyl-3-methyl-4-trifluoromethyl-phenol, 4-tert-butyl-6-cyclopropyl-2-fluoro-34rinuoromethyl- phenol, 2-fluoro-6-isopropyl-3-methyl-4-(l-methyl-cyclopropyl)-phenol, 2-fluoro-6-isopropyl-3- methyl-4-[l-(2,2,2-trifluoro-ethyl)-cyclopropyl]-phenol, 2-fluoro-6-isopropyl-3-methyl-4-(l-penta- fluoroethyl-cyclopropyl)-phenol, 2-fluoro-3-methyl-4-(2,2,3,3,3-pentafluoro-propyl)-6-(2,2,2-tri- nuoro-l-methyl-ethyl)-phenol, 2-fluoro-3-methyl-4-pentafluoroethyl-6-(2,2,2-trifluoro-l-methyl- ethyl)-phenol, 3 -cyclopropyl-2-fluoro-4-(2,2,2-trifluoro- 1 , 1 -dimethyl-ethyl)-6-( 1 -trifluoromethyl- cyclopropyl)-phenol, 2-fluoro-3-methyl-4,6-bis-(l-methyl-cyclopropyl)-phenol, 2-fluoro-3-methyl- 4-(l -metbyl-cyclopropyl)-6-( 1 -trifluoromethyl-cyclopropyl)-phenol, 2-fluoro-3-methyl-4,6-bis-(l - trifluoromethyl-cyclopropyl)-phenol, and 2-fluoro-3-methyl-6-(l-methyl-cyclopropyl)-4-(2,2,2- trifluoro- 1 , 1 -dimethyl-ethyl)-phenol. 159. The compound or pharmaceutically acceptable salt of Claim 139, wherein the compound is selected from the group consisting of 4-tert-butyl-2-fluoro-6-isopropyl-3-methyl-phenol, 4-tert- butyl-2-fluoro-6-isopropyl-3-trifluoromethyl-phenol, 2-fluoro-6-isopropyl-3-methyl-4-(2,2,2-tri- fluoro-1, l-dimethyl-ethyl)-phenol, 2-bromo-6-isopropyl-3-methyl-4-trifluoromethyl-phenol, 4-tert- butyl-6-cyclopropyl-2-fluoro-3-trifluoromethyl-phenol, 2-fluoro-6-isopropyl-3-methyl-4-(l-methyl- cyclopropyl)-phenol, 2-fluoro-6-isopropyl-3-methyl-4-[l-(2,2,2-trifluoro-ethyl)-cyclopropyl]- phenol, 2-fluoro-6-isopropyl-3-methyl-4-(l-pentafluoroethyl-cyclopropyl)-phenol, 2-fluoro-3- methyl-4-(2,2,3,3,3-pentafluoro-propyl)-6-(2,2,2-trifluoro-l-methyl-ethyl)-phenol, 2-fluoro-3- methyl-4-pentafluoroethyl-6-(2,2,2-trifluoro-l-methyl-ethyl)-phenol, 3-cyclopropyl-2-fluoro-4- (2,2,2-trifluoro- 1 , 1 -dimethyl-ethyl)-6-( 1 -trifluoromethyl-cyclopropyl)-phenol, 2-fluoro-3 -methyl- 4,6-bis-(l-methyl-cyclopropyl)-phenol, 2-fluoro-3-methyl-4-(l-methyl-cyclopropyl)-6-(l-trifluoro- methyl-cyclopropyl)-phenol, 2-fluoro-3-methyl-4,6-bis-(l-trifluoromethyl-cyclopropyl)-phenol, and 2-fluoro-3-methyl-6-(l-methyl-cyclopropyl)-4-(2,2,2-trifluoro-l,l-dimethyl-ethyl)-phenol.

160. The method of Claim 108, wherein the compound is selected from the group consisting of 3- bromo-4-tert-butyl-2-fluoro-6-isopropyl-phenol, 4-tert-butyl-3-chloro-2-fluoro-6-isopropyl-phenol, 4-tert-butyl-2,3-difluoro-6-isopropyl-phenol, 3-bromo-6-cyclopropyl-2-fluoro-4-(2,2,2-trifluoro-l ,l- dimethyl-ethyl)-phenol, 3-bromo-2-fluoro-6-isopropyl-4-trifluoromethyl-phenol, 3-bromo-2-fluoro- 6-isopropyl-4-( 1 -methyl-cyclopropyl)-phenol, 3 -bromo-2-fiuoro-6-isopropyl-4-(l -trifluoromethyl- cyclopropyl)-phenol, 3-bromo-6-cyclopropyl-2-fluoro-4-(l-trifluoromethyl-cyclopropyl)-phenol, 4- tert-butyl-2-fluoro-6-isopropyl-3-trifluoromethoxy-phenol, 3-tert-butoxy-2-fluoro-6-isopropyl-4- trifluoromethyl-phenol, 2-fluoro-6-isopropyl-4-( 1 -methyl-cyclopropyl)-3-trifluoromethoxy-phenol,

3- bromo-2-fluoro-4-pentafluoroethyl-6-(2,2,2-trifluoro-l-methyl-ethyl)-phenol, 3-bromo-2-fluoro-4- pentafluoroethyl-6-(2,2,2-trifluoro- 1 -methyl-ethyl)-phenol, 3-bromo-2-fluoro-6-isopropyl-4-

(2,2,3,3, 3-pentafluoro-propyl)-phenol, 3-bromo-2-fluoro-4-(2,2,2-trifluoro-l,l-dimethyl-ethyl)-6-(l- trifluoromethyl-cyclopropyl)-phenol, 3-bromo-2-fluoro-4-(l-methyl-cyclopropyl)-6-(l-trifluoro- methyl-cyclopropyl)-phenol, 3-bromo-2-fluoro-6-(l-methyl-cyclopropyl)-4-(l-trifluoromethyl- cyclopropyl)-phenol, 3 -bromo-2-fluoro-4,6-bis-( 1 -trifluoromethyl-cyclopropyl)-phenol, 3 -bromo-2- nuoro-6-(l-methyl-cyclopropyl)-4-(2,2,2-trifluoro-l,l-dimethyl-ethyl)-phenol, and 3-bromo-2- fluoro-4-(2,2,2-trifluoro-l,l-dimethyl-ethyl)-6-(l-trinuoromethyl-cyclopropyl)-phenoL

161. The compound or pharmaceutically acceptable salt of Claim 125, wherein the compound is selected from the group consisting of 3-bromo-4-tert-butyl-2-fluoro-6-isopropyl-phenol, 4-tert- butyl-3-chloro-2-fluoro-6-isopropyl-phenol, 4-tert-butyl-2,3-difluoro-6-isopropyl-phenol, 3-bromo- 6-cyclopropyl-2-fluoro-4-(2,2,2-trifluoro-l , 1 -dimethyl-ethyl)-phenol, 3-bromo-2-fluoro-6-iso- propyl-4-trifluoromethyl-phenol, 3 -bromo-2-fluoro-6-isopropyl-4-( 1 -methyl-cyclopropyl)-phenol, 3 - bromo-2-fluoro-6-isopropyl-4-( 1 -trifluoromethyl-cyclopropyl)-phenol, 3 -bromo-6-cyclopropyl-2- fluoro-4-( 1 -trifluoromethyl-cyclopropyl)-phenol, 4-tert-butyl-2-fluoro-6-isopropyl-3-trifluoro- methoxy-phenol, 3-tert-butoxy-2-fiuoro-6-isopropyl-4-trifluoromethyl-phenol, 2-fiuoro-6-isopropyl-

4- (l-methyl-cyclopropyl)-3-trifluoromethoxy-phenol, 3-bromo-2-fluoro-4-pentafluoroethyl-6-(2,2,2- trifluoro-l-methyl-ethyl)-phenol, 3-bromo-2-fluoro-4-pentafluoroethyl-6-(2,2,2-trifluoro-l-methyl- ethyl)-phenol, 3-bromo-2-fluoro-6-isopropyl-4-(2,2,3,3,3-pentafluoro-propyl)-phenol, 3-bromo-2- fluoro-4-(2,2,2-trifluoro-l,l-dimethyl-ethyl)-6-(l-trifluoromethyl-cyclopropyl)-phenol, 3-bromo-2- fluoro-4-(l-methyl-cyclopropyl)-6-(l-trifluoromethyl-cyclopropyl)-phenol, 3-bromo-2-fluoro-6-(l- methyl-cyclopropyl)-4-( 1 -trifluoromethyl-cyclopropyl)-phenol, 3-bromo-2-fluoro-4,6-bis-(l - trifluoromethyl-cyclopropyl)-phenol, 3-bromo-2-fluoro-6-(l-methyl-cyclopropyl)-4-(2,2,2-trifluoro- 1 , 1 -dimethyl-ethyl)-phenol, and 3-bromo-2-nuoro-4-(2,2,2-trifluoro- 1 , 1 -dimethyl-ethyl)-6-( 1 - trifluoromethyl-cyclopropyl)-phenol.

162. A compound or pharmaceutically acceptable salt of the compound, wherein the compound has the structure of

Formula (IX):

(IX) wherein:

R² is selected from the group consisting of haloalkyl and cycloalkyl;

R⁵ is selected from the group consisting of haloalkyl and cycloalkyl; and

R⁶ is halo.

163. The method of any one of Claims 106-124, 126-137, 140-148, 155, 158, or 160, wherein the compound is deuterated.

164. The compound or pharmaceutically acceptable salt of any one of Claims 125, 138, 139, 149- 154, or 156-161 wherein the compound is deuterated. 165. A method of treating a neurological or an inflammatory condition comprising administering a therapeutically effective amount of a compound or pharmaceutically acceptable salt of the compound, wherein the compound has a structure of Formula (XII):

(XII)

R is selected from the group consisting of an ester, a carbonate, a phosphate, a carbamate, a sulfamate, and an acylmethylester;

R² is selected from the group consisting of alkyl, haloalkyl, and cycloalkyl, wherein the alkyl or haloalkyl is optionally substituted with one or more cycloalkykl substituents;

R⁴ is selected from the group consisting of H, halo, alkyl, alkoxy, haloalkyl, haloalkoxy and cycloalkyl, wherein alkyl or haloalkyl is optionally substituted with one or more cycloalkyl substituents, wherein alkoxy alkyl hydrogens may be optionally substituted with one or more substituents independently selected from the group consisting of alkyl and halo, and wherein R⁴ is not methyl;

R⁵ is selected from the group consisting of alkyl, haloalkyl, cycloalkyl, halo, and alkoxy, wherein the alkoxy may be optionally substituted with one or more substituents independently selected from the group consisting of alkyl and haloalkyl; and

R⁶ is halo.

166. The method of Claim 165, wherein the compound has a structure of Formula (XIII):

wherein D¹ is alkyl, aryl, cycloalkyl, heterocycloalkyl, heteroalkyl, heteroaryl, heteroaralkyl, carbonylalkyl, or phosphonooxyalkyl, optionally substituted with one or more substituents selected from the group consisting of alkyl, carboxylate, heteroalkyl, monocyclic ring, bicyclic ring, and hydroxyl moieties. The method of Claim 166, wherein the compound has a structure of Formula (XIV):

wherein:

D² and D³ together with the carbon atom to which they are bonded form a cycloalkyl or cycloheteroalkyl ring, or alternatively D² and D³ are each independently selected from the group consisting of hydrogen, alkyl, and heteroalkyl,;

A, Y, and one of D² or D³ together with the atoms to which they are bonded to form a cycloheteroalkyl ring, or alternatively A is selected from the group consisting of hydrogen, phosphono, alkyl, aryl, arylalkyl, heteroalkyl, heteroaryl, and heteroarylalkyl;

X is selected from the group consisting of— ND⁴— ,— O— ,— CI¾— , and— S— ;

Y is selected from the group consisting of— O— and— ND⁴— ;

n is an integer from 1 to 5; and

D⁴ is selected from the group consisting of hydrogen, alkyl, and arylalkyl.

168. The method of Claim 167, wherein D² and D³ are each hydrogen, X is— CH₂— , Y is— O— , A is phosphono, and n=l.

169. The method of Claim 165, wherein R¹ is selected from the group consisting of-P-(0)(OD⁵)₂,

CH₃

-CH₂-0-P-(0)(OD⁵)₂, -(CH₂)₂-0-P-(0)(OD⁵)₂, and -CH₂-0-P-(0)(OD⁵)₂, and further wherein D⁵ is H or a pharmaceutically acceptable cation.

170. The method of Claim 169, wherein the pharmaceutically acceptable cation is selected from the group consisting of Li⁺, Na⁺, and K⁺. 171. The method of Claim 165, wherein R¹ is selected from the group consisting of

172. The method of Claim 165, wherein R¹ is selected from the group consisting of

2

173. The method of Claim 165, wherein R¹ is -

174. The method of any one of the previous claims wherein:

alkyl is selected from the group consisting of methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, sec-butyl, pentanyl, isopentanyl, and neopentanyl;

haloalkyl is selected from the group consisting of fluoromethyl, 1 -fluoroethyl, 2-fluoroethyl, 1- fluoropropyl, 2-fluoropropyl, 3-fluoropropyl, chloromethyl, 1 -chloroethyl, 2-chloroethyl, 1- chloropropyl, 2-chloropropyl, 3-chloropropyl, bromomethyl, l-bromoethyl, 2-bromoethyl, 1- bromopropyl, 2-bromopropyl, and 3-bromopropyl; and cycloalkyl is selected from the group consisting of cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.

received by the International Bureau on 24 March 2016 (24.03.2016)

What is claimed is:

1. A method of treating a neurological or an inflammatory condition comprising administering a therapeutically effective amount of a compound or pharmaceutically acceptable salt of the compound, wherein the compound has the structure of Formula (I):

wherein:

R² is selected from the group consisting of alkyl, haloalkyl, and cycloalkyl;

R⁴ is selected from the group consisting of halo and alkoxy, wherein the alkoxy may be optionally substituted with one or more substituents independently selected from the group consisting of alkyl and halo, and wherein R⁴ is not methyl; and

R³ is selected from the group consisting of alkyl, haloalkyl, and cycloalkyl.

2. The method of claim 1 wherein each of R² and R^D has between one and five carbons.

3. The method of claim 1 wherein the condition is epilepsy, seizures, or convulsions.

4. The method of claim 1 wherein the condition is neuropathic pain or fibromyalgia.

5. The method of claim 1 wherein the condition is a psychological disorder.

6. The method of claim 5 wherein the psychological disorder is anxiety, mania, bipolar disorder, or depression.

7. The method of claim 1, wherein the condition is Alzheimer's Disease, Huntington's Disease, Multiple Sclerosis, Parkinson's disease, Tourette's Syndrome, tinnitus, or tremors.

8. The method of Claims 1 or 3, wherein:

R is selected from the group consisting of alkyl, haloalkyl, and cycloalkyl;

R⁴ is halo.

9. The method of Claim 8, wherein:

R⁴ is selected from the group consisting of Br, CI, and F.

10. The method of Claim 9, wherein:

R² is alkyl; and

R³ is alkyl having two or more carbons.

1 1. The method of Claim 10, wherein the compound is selected from a group consisting of: 4- chloro-5-terr-butyl-2-methyl-phenol; 4-chloro-2-isopropyl-5-methyl-phenol; 4-fluoro-2-iso propyl- 5-methyl-phenol; 4-chloro-2,5-diisopropyl-phenol; 4-bromo-5-isopropyl-2-methylphenol; 4-bromo- 2-isopropyl-5-methyl-phenol; 4-bromo-2-ier/-butyl-5-isopropyl-phenol; 4-bromo-5-reri-butyl-2- methyl-phenol; and 4-fluoro-5-tert-butyl-2-methyl-phenol.

The method of Claim 1, wherein the compound has the structure of Formula (II):

wherein:

R is selected from the group consisting of alkyl, haloalkyl, and cycloalkyl;

R⁴ is selected from the group consisting of Br, CI, and F; and R⁸, R⁹ and R¹⁰ are each independently selected from the group consisting of H, alkyl, and haloalkyl.

13. The method of Claim 1, wherein the compound has the structure of Formula (III):

wherein:

R² is selected from the group consisting of alkyl, haloalkyl, and cycloalkyl;

R⁵ is selected from the group consisting of alkyl, haloalkyl, and cycloalkyl; and

R₇ is selected from the group consisting of alkyl and haloalkyl.

14. The method of Claim 13, wherein:

R² is selected from the group consisting of alkyl, haloalkyl, and cycloalkyl;

R^D is selected from the group consisting of alkyl, haloalkyl, and cycloalkyl; and

R₇ is alkyl.

The method of Claim 14, wherein the compound has the structure of Formula (IV):

wherein:

R² is selected from the group consisting of alkyl, haloalkyl, and cycloalkyl; and

R³ is selected from the group consisting of alkyl, haloalkyl, and cycloalkyl.

16. The method of Claim 15, wherein:

R² is selected from the group consisting of alkyl and cycloalkyl; and

R³ is selected from the group consisting of alkyl and cycloalkyl.

A compound selected from the group consisting of: 4-bromo-5-ethyl-2-methyl-phenol; 4- fluoro-5-isopropyl-2-methyl-phenol; 4-bromo-5-terr-butyl-2-methyl-phenol; 4-bromo-5- cyclopropyl-2-methyl -phenol; 4-bromo-2-ethyl-5-isopropyl -phenol; 4-chloro-2-ethyl-5-isopropyl- phenol; 2-ethyl-4-fluoro-5-isopropyl phenol; 4-bromo-5-isopropyl-2-propyl-phenol, 5-isopropyl-2- propyl-phenol; and 4-bromo-2,5-isopropyl-phenol.

18. A compound selected from the group consisting of: 4-bromo-2-methyl-5-(2,2,2-trifluoro-l- methyl-ethyl)-phenol; 4-bromo-5-(2-fluoro- l-methyl-ethyl)-2-methyl -phenol; 4-bromo-2-methyl-5- (2,2,2-trifluoro- l-trifluoromethyl-ethyl)-phenol; 4-bromo-2-trifluoromethyl-5-(2,2,2-trifiuoro- 1- methyl-ethyI)-phenol; 4-bromo-2-cyclopropyl-5-isopropyl-phenol; 4-bromo-2,5-dicyclopropyl- phenol; 5-isopropyl-2-methyl-4-trifluoromethoxy-phenol; 2-cyclopropyl-5-isopropyl-4- trifiuoromethoxy-phenol; 5-cyclopropyl-2-methyl-4-trifluoromethoxy-phenol; 2,5-dicyclopropyl-4- trifluoromethoxy-phenol; 4-½rr-butoxy-5-cyclopropyl-2-methyl-phenol; 4-rert-butoxy-2- cyclopropyl-5-methyl-phenol; 4-ter/-butoxy-2,5-dicyclopropyl-phenol; 4-isopropoxy-5-isopropyl-2- methyl -phenol; 4-bromo-5-isopropyl-2-trifluoromethyl-phenol; 4-bromo-5-(2-fluoro- 1 -methyl- ethyl)-2-methyl-phenol; and 4-rm-butoxy-5-isopropyl-2-methyl-phenol.

19. A compound or pharmaceutically acceptable salt of the compound, wherein the compound has the structure of Formula (V):

wherein:

selected from the group consisting of haloalkyl and cycloalkyl; and selected from the group consisting of haloalkyl and cycloalkyl.

20. A compound of Claim 19, wherein:

R² is selected from the group consisting of trifluoroalkyl and cycloalkyl

R³ is selected from the group consisting of trifluoroalkyl and cycloalkyl.

21. A compound selected from the group consisting of: 5-(l,2-dimethyl-propyl)-2-methyl-phenol; 5-isobutyl-2-methyl-phenol; 5-cyclopentyl-2-methyl-phenol; 5-sec--butyl-2-ethyl-phenol; 5-butyl-2- propyl -phenol; 5-isopropyl-2-propyl-phenol; 5-y-?obutyl-2-propyl -phenol; 5-tert-butyl-2-propyl- phenol; 2-butyl-5-isopropyl-phenol; 2-butyl-5-sec-butyl-phenol; 5-(tert-butyl)-2-butylphenol; 2- isopropyl-5-propyl-phenol; 5-sec-butyl-2-isopropyl-phenol; 2-sec-butyl-5-ethyl-phenol; 2-.sec-butyl- 5-propyl- phenol; 5-butyl-2-,sec-butyl-phenol; 2-.sec-butyl-5-isopropyl- phenol; 5-sec-buty\-2-tert- butyl-phenol; 2-methyl-5-(2,2,2-trifluoro-l-methyl-ethyl)-phenol; 5-(2-fluoro-l -methyl -ethyl)-2- methyl-phenol; 2-methyl-5-(2,2,2-trifluoro-l-trifluoromethyl-ethyl)-phenol; 2-trifiuoromethyl-5- (2,2,2-trifluoro-l-methyl-ethyl)-phenol; 5-isopropyl-2-(l-methyl-butyl)-phenol; 2-isopropyl-5- isopropyl-phenol; 2-cyclopropyl-5-isopropyl-phenol; and 2,5-dicyclopropyl-phenol.

22. A compound or pharmaceutically acceptable salt of the compound, wherein the compound has the structure of Formula (I):

whe

l, and -CF₃;

R⁴ is halo;

R³ is selected from the group consisting of fluoroalkyl and a three, four, or five carbon cycloalkyl.

23. The compound of Claim 22, wherein:

R⁴ is selected from the group consisting of Br, CI, and F.

24. A compound or pharmaceutically acceptable salt of the compound, wherein the compound has the structure of Formula (III):

(HI)

wherein:

R and R⁵ are each independently selected from the group consisting of alkyl and cycloalkyl, wherein at least one of R² and R³ is cycloalkyl; and

R₇ is selected from the group consisting of isopropyl, tert-butyi, and haloalkyl.

25. A compound of Claim 24, wherein:

R₇ is selected from the group consisting of isopropyl and tert-buty\.

26. A compound or pharmaceutically acceptable salt of the compound of Claim 22, wherein the compound has the structure of Formula (IV):

wherein:

R >2 is selected from the group consisting of alkyl, and cycloalkyl; and

R³ is selected from the group consisting of alkyl, and cycloalkyl.

27. A method of treating epilepsy, seizures, or convulsions, the method comprising administering a therapeutically effective amount of a compound or of a pharmaceutically acceptable salt of the compound, wherein the compound has the structure of Formula (I):

wherein:

R² and R⁵ are each independently selected from the group consisting of methyl, isopropyl, and f erf-butyl; and

R⁴ is selected from the group consisting of Br, CI, and F.

28. The method of any one of Claims 1-16 or 27, wherein the compound is deuterated.

29. The compound or pharmaceutically acceptable salt of any one of Claims 17-26, wherein the compound is deuterated.

30. A method of treating a neurological or an inflammatory condition comprising administering a therapeutically effective amount of a compound or pharmaceutically acceptable salt of the compound, wherein the compound has a structure of Formula (V):

wherein:

R¹ is selected from the group consisting of an ester, a carbonate, a phosphate, a carbamate, a sulfamate, and an acylmethylester;

R² is selected from the group consisting of alkyl, haloalkyl, and cycloalkyl;

R⁴ is selected from the group consisting of H, halo, and alkoxy, wherein the alkoxy may be optionally substituted with one or more substituents independently selected from the group consisting of alkyl and halo, and wherein R⁴ is not methyl; and

R⁵ is selected from the group consisting of alkyl, haloalkyl, and cycloalkyl.

31. The method of Claim 30, wherein the compound has a structure of Formula (VI):

wherein D¹ is alkyl, aryl, cycloalkyl, heterocycloalkyl, heteroalkyl, heteroaryl, heteroaralkyl, carbonylalkyl, or phosphonooxyalkyl, optionally substituted with one or more substituents selected from the group consisting of alkyl, carboxylate, heteroalkyl, monocyclic ring, bicyclic ring, and hydroxyl moieties.

The method of Claim 31, wherein the compound has a structure of Formula (VII):

wherein:

D² and D³ together with the carbon atom to which they are bonded form a cycloalkyl or cycloheteroalkyl ring, or alternatively D² and D³ are each independently selected from the group consisting of hydrogen, alkyl, and heteroalkyl,;

A, Y, and one of D or D together with the atoms to which they are bonded to form a cycloheteroalkyl ring, or alternatively A is selected from the group consisting of hydrogen, phosphono, alkyl, aryl, arylalkyl, heteroalkyl, heteroaryl, and heteroarylalkyl;

X is selected from the group consisting of— ND⁴— ,— O— ,— CH₂— , and— S— ;

Y is selected from the group consisting of— O— and— ND⁴— ;

n is an integer from 1 to 5; and

D⁴ is selected from the group consisting of hydrogen, alkyl, and arylalkyl.

33. The method of Claim 32, wherein D² and D³ are each hydrogen, X is— CH₂— , Y is— O— , A is phosphono, and n=l.

34. The method of Claim 30, wherein R¹ is selected from the group consisting of -P-(0)(OD^:')₂,

CH₃

-CH₂-0-P-(0)(OD⁵)₂, -(CH₂)₂-0-P-(0)(OD⁵)₂, and -CH₂-0-P-(0)(OD⁵)₂, and further wherein D³ is H or a pharmaceutically acceptable cation.

35. The method of Claim 34, wherein the pharmaceutically acceptable cation is selected from the group consisting of Li⁺, Na⁺, and K⁺.

36. The method of Claim 30, wherein R¹ is selected from the group consisting of

37. The method of Claim 30, wherein R is selected from the group consisting of

38. The method of Claim 30, wherein R¹ is

39. The method of any one of the previous claims wherein:

alkyl is selected from the group consisting of methyl, ethyl, propyl, isopropyl, butyl, isobutyl, ieri-butyl, .sec-butyl, pentanyl, isopentanyl, and neopentanyl;

haloalkyl is selected from the group consisting of fluoromethyl, 1-fluoroethyl, 2-fluoroethyl, 1- fluoropropyl, 2-fluoropropyl, 3-fluoropropyl, chloromethyl, 1-chloroethyl, 2-chloroethyl, 1- chloropropyl, 2-chloropropyl, 3-chloropropyl, bromomethyl, 1-bromoethyl, 2-bromoethyl, 1- bromopropyl, 2-bromopropyl, and 3-bromopropyl; and cycloalkyl is selected from the group consisting of cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.

40. A method of treating a neurological or an inflammatory condition comprising administering a therapeutically effective amount of a compound or pharmaceutically acceptable salt of the compound, wherein the compound has a structure of Formula (I):

wherein:

R² is selected from the group consisting of alkyl, haloalkyl, and cycloalkyl, wherein the alkyl or haloalkyl is optionally substituted with one or more cycloalkykl substituents;

R⁴ is selected from the group consisting of alkyl, haloalkyl, and cycloalkyl, wherein the alkyl or haloalkyl is optionally substituted with one or more cycloalkykl substituents, and wherein R⁴ is not methyl; and

R³ is selected from the group consisting of alkyl, haloalkyl, and cycloalkyl.

41. The method of Claim 40 wherein each of R², R⁴, and R³ has between one and five carbons.

42. The method of Claim 41 wherein the condition is epilepsy, seizures, or convulsions.

43. The method of Claim 40 wherein the condition is neuropathic pain or fibromyalgia.

44. The method of Claim 40 wherein the condition is a psychological disorder.

45. The method of Claim 44 wherein the psychological disorder is anxiety, mania, bipolar disorder, or depression.

46. The method of Claim 40, wherein the condition is Alzheimer's Disease, Huntington's Disease, Multiple Sclerosis, Parkinson's disease, Tourette' s Syndrome, tinnitus, or tremors.

47. The method of Claim 40, wherein the compound has a structure of Formula (II):

wherein:

R² is selected from the group consisting of alkyl, haloalkyl, and cycloalkyl;

R⁸ and R⁹ form a cycloalkyl of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, or 14 carbons or R⁸ and R⁹ are each independently selected from the group consisting of H, alkyl, and haloalkyl;

R¹⁰ is selected from the group consisting of H, alkyl, and haloalkyl;

R¹² and R¹³ form a cycloalkyl of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, or 14 carbons or R¹² and R¹³ are each independently selected from the group consisting of H, alkyl, and haloalkyl; and R^!4 is selected from the group consisting of H, alkyl, and haloalkyl.

The method of Claim 47, wherein halo is chloro, bromo, or fluoro.

The method of Claim 48, wherein the halo is fluoro.

The method of Claim 40, wherein the compound has a structure of Formula (III):

R³ is selected from the group consisting of alkyl, haloalkyl, and cycloalkyl;

R¹² and R¹³ form a cycloalkyl of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 1 1, 12, 13, or 14 carbons or R¹² and R¹³ are each independently selected from the group consisting of H, alkyl, and haloalkyl; and R¹⁴ is selected from the group consisting of H, alkyl, and haloalkyl;

R¹⁵ and R¹⁶ form a cycloalkyl of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 1 1, 12, 13, or 14 carbons or R¹⁵ and R¹⁶ are each independently selected from the group consisting of H, alkyl, and haloalkyl; and R¹⁷ is selected from the group consisting of H, alkyl, and haloalkyl.

51. The method of Claim 50, wherein halo is chloro, bromo, or fluoro.

52. The method of Claim 51, wherein the halo is fluoro.

53. The method of Claim 47, wherein:

R¹² and R¹³ form a cycloalkyl moiety; and

R¹⁴ is selected from the group consisting of alkyl and haloalkyl.

54. The method of Claim 50, wherein:

R¹² and R¹³ form a cycloalkyl moiety;

R^l3 and R¹⁶ form a cycloalkyl moiety; and

R¹⁴ and R¹⁷ are each independently selected from the group consisting of alkyl and haloalkyl.

55. The method of Claim 50, wherein:

R³ is selected from the group consisting of methyl and isopropyl;

R¹² is selected from the group consisting of H, halo, methyl, and cycloalkyl comprising R¹³; R¹³ is selected from the group consisting of H, halo, methyl, trihalomethyl, and cycloalkyl comprising R¹²;

R¹⁴ is selected from the group consisting of halo, methyl, trihalomethyl and pentahaloethyl;

R¹³ is selected from the group consisting of H, methyl, and trihalomethyl.

R¹⁶ is selected from the group consisting of H and cycloalkyl comprising R¹⁷; and

R¹⁷ is selected from the group consisting of H, methyl, and cycloalkyl comprising R¹⁶.

56. The method of Claim 55 wherein the halo is chloro, bromo, or fluoro.

57. The method of Claim 56, wherein the halo is fluoro.

58. The method of Claim 57, wherein the compound is selected from the group consisting of: 5- isopropyl-2-methyl-4-trifluoromethyl-phenol; 2,5-diisopropyl-4-trifluoromethyl -phenol; 4-( 1,1- difluoroethyl)-2-isopropyl-5-methyl-phenol; 2-isopropyl-5-methyl-4-trifluoromethyl-phenol; 2- isopropyl-5-methyl-4-( l-methyl-cyclopropyl)-phenol; 2-isopropyl-5-methyl-4-(l-trifluoro-methyl- cyclopropyl)-phenol; 2-isopropyl-5-methyl-4-(2,2,3,3,3-pentafluoro-propyl)-phenol; 2-isopropyl-5- methyl-4-pentafluoroethyl-phenol; 2-isopropyl-5-methyl-4-(2,2,2-trifluoro- 1 , 1-dimethyl-ethyl)- phenol; 4-½rr-butyl-5-methyl-2-(2,2,2-trifluoro- l-methyl-ethyl)-phenol; 4-fcrt-butyl-5-methyl-2-(l- methyl-cyclopropyl)-phenol; and 4-tert-butyl-5-methyl-2-(l-trifiuoro-methyl-cyclopropyl)-phenol.

59. A compound or pharmaceutically acceptable salt of the compound, wherein the compound has a structure of Formula (III): wherein:

R³ is selected from the group consisting of methyl and isopropyl;

1 ? 13

R is selected from the group consisting of H, halo, methyl, and cycloalkyl comprising R ; R¹³ is selected from the group consisting of H, halo, methyl, trihalomethyl, and cycloalkyl comprising R¹²;

R¹⁴ is selected from the group consisting of halo, methyl, trihalomethyl and pentahaloethyl;

R^{l 3} is selected from the group consisting of H, methyl, and trihalomethyl.

R¹⁶ is selected from the group consisting of H and cycloalkyl comprising R¹⁷; and

1 7 16

R is selected from the group consisting of H, methyl, and cycloalkyl comprising R .

60. A compound or pharmaceutically acceptable salt of the compound, wherein the compound is selected from the group consisting of the species of Table 1 , except 4-tert-butyl-5-ethyl-2-methyl- phenol.

61. The compound or pharmaceutically acceptable salt of Claim 60, wherein the compound is selected from the group consisting of 5-isopropyl-2-methyl-4-trifluoromethyl -phenol; 2,5- diisopropyl-4-trifluoromethyl-phenol; 4-( l,l-difluoroethyl)-2-isopropyl-5-methyl-phenol; 2- isopropyl-5-methyl-4-trifluoromethyl-phenol; 2-isopropyl-5-methyl-4-( 1 -methyl -cyclopropyl)- phenol ; 2-isopropyl-5 -methyl-4-( 1 - trifluoro-methyl-cyclopropyl)-phenol ; 2-isopropyl-5-methyl-4- (2,2,3,3, 3-pentafluoro-propyl)-phenol; 2-isopropyl-5-methyl-4-pentafluoroethyl-phenol; 2- isopropyl-5-methyl-4-(2,2,2-trifluoro- l,l-dimethyl-ethyl)-phenol; 4-tert-butyl-5-methyl-2-(2,2,2- trifluoro- l-methyl-ethyl)-phenol; 4-rm-butyl-5-methyl-2-(l-methyl-cyclopropyl)-phenol; and 4- rer/-butyl-5-methyl-2-( 1 -trifluoro-methyl-cyclopropyl)-phenol.

62. The method of any one of Claims 40-58, wherein the compound is deuterated.

63. The compound or pharmaceutically acceptable salt of any one of Claims 59-61 , wherein the compound is deuterated.

64. A method of treating a neurological or an inflammatory condition comprising administering a therapeutically effective amount of a compound or pharmaceutically acceptable salt of the compound, wherein the compound has a structure of Formula (IV):

wherein:

R¹ is selected from the group consisting of an ester, a carbonate, a phosphate, a carbamate, a sulfamate, and an acylmethylester;

R² is selected from the group consisting of alkyl, haloalkyl, and cycloalkyl, wherein the alkyl or haloalkyl is optionally substituted with one or more cycloalkykl substituents;

R⁴ is selected from the group consisting of alkyl, haloalkyl, and cycloalkyl, wherein the alkyl or haloalkyl is optionally substituted with one or more cycloalkykl substituents, and wherein R⁴ is not methyl; and

R⁵ is selected from the group consisting of alkyl, haloalkyl, and cycloalkyl.

The method of Claim 64, wherein the compound has a structure of Formula (V):

wherein D is alkyl, aryl, cycloalkyl, heterocycloalkyl, heteroalkyl, heteroaryl, heteroaralkyl, carbonylalkyl, or phosphonooxyalkyl, optionally substituted with one or more substituents selected from the group consisting of alkyl, carboxylate, heteroalkyl, monocyclic ring, bicyclic ring, and hydroxyl moieties.

wherein:

D² and D³ together with the carbon atom to which they are bonded form a cycloalkyl or cycloheteroalkyl ring, or alternatively D² and D³ are each independently selected from the group consisting of hydrogen, alkyl, and heteroalkyl,;

A, Y, and one of D² or D³ together with the atoms to which they are bonded to form a cycloheteroalkyl ring, or alternatively A is selected from the group consisting of hydrogen, phosphono, alkyl, aryl, arylalkyl, heteroalkyl, heteroaryl, and heteroarylalkyl;

X is selected from the group consisting of— ND⁴— ,— O— ,— CH₂— , and— S— ;

Y is selected from the group consisting of— O— and— ND⁴— ;

n is an integer from 1 to 5; and

D⁴ is selected from the group consisting of hydrogen, alkyl, and arylalkyl.

67. The method of Claim 66, wherein D² and D³ are each hydrogen, X is— CH₂— , Y is— O— , A is phosphono, and n=l.

68. The method of Claim 64, wherein R¹ is selected from the group consisting of -P-(0)(OD^:>)₂,

CH₃

-CH₂-0-P-(0)(OD⁵)₂, -(CH₂)₂-0-P-(0)(OD⁵)₂, and -CH₂-0-P-(0)(OD⁵)₂, and further wherein D³ is H or a pharmaceutically acceptable cation.

69. The method of Claim 68, wherein the pharmaceutically acceptable cation is selected from the group consisting of Li⁺, Na⁺, and K⁺.

70. The method of Claim 64, wherein R¹ is selected from the group consisting of

40. The method of Claim 64, wherein R¹ is selected from the group consisting of

71. The method of Claim 64, wherein R¹ is

72. The method of any one of the previous claims wherein:

alkyl is selected from the group consisting of methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, sec-butyl, pentanyl, isopentanyl, and neopentanyl;

haloalkyl is selected from the group consisting of fluoromethyl, 1-fluoroethyl, 2-fluoroethyl, 1- fluoropropyl, 2-fluoropropyl, 3-fluoropropyl, chloromethyl, 1-chloroethyl, 2-chloroethyl, 1- chloropropyl, 2-chloropropyl, 3-chloropropyl, bromomethyl, 1-bromoethyl, 2-bromoethyl, 1- bromopropyl, 2-bromopropyl, and 3-bromopropyl; and cycloalkyl is selected from the group consisting of cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.

73. A method of treating a neurological or an inflammatory condition comprising administering a therapeutically effective amount of a compound or pharmaceutically acceptable salt of the compound, wherein the compound has a structure of Formula (I):

R² is selected from the group consisting of alkyl, haloalkyl, and cycloalkyl, wherein the alkyl or haloalkyl is optionally substituted with one or more cycloalkyl substituents;

R⁴ is selected from the group consisting of alkyl, haloalkyl, and cycloalkyl, wherein the alkyl or haloalkyl is optionally substituted with one or more cycloalkyl substituents, and wherein R⁴ is not methyl; and

R³ is selected from the group consisting of halo, and alkoxy, wherein the alkoxy may be optionally substituted with one or more substituents independently selected from the group consisting of alkyl and halo.

74. The method of Claim 73 wherein each of R², R⁴, and R³ has between one and five carbons.

75. The method of Claim 73 wherein the condition is epilepsy, seizures, or convulsions.

76. The method of Claim73 wherein the condition is neuropathic pain or fibromyalgia.

77. The method of Claim73 wherein the condition is a psychological disorder.

78. The method of Claim 77 wherein the psychological disorder is anxiety, mania, bipolar disorder, or depression.

79. The method of Claim 73, wherein the condition is Alzheimer's Disease, Huntington's Disease, Multiple Sclerosis, Parkinson's disease, Tourette's Syndrome, tinnitus, or tremors.

80. The method of Claim 74, wherein R² and R⁴ are not identical.

81. The method of Claim 74, wherein the compound has a structure of Formula (II):

wherein,

R⁵ is halo;

R⁸ and R⁹ form a cycloalkyl of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, or 14 carbons or R⁸ and R⁹ are each independently selected from the group consisting of H, alkyl, halo, and haloalkyl;

R¹⁰ is selected from the group consisting of H, alkyl, halo, and haloalkyl;

R¹² and R¹³ form a cycloalkyl of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, or 14 carbons or R¹² and R¹³ are each independently selected from the group consisting of H, alkyl, halo, and haloalkyl; and

R¹⁴ is selected from the group consisting of H, alkyl, halo, and haloalkyl.

The method of Claim 80, wherein the compound has a structure of Formula (II) wherein,

R⁵ is halo;

R⁸ and R⁹ form a cycloalkyl of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 1 1, 12, 13, or 14 carbons or R⁸ and R⁹ are each independently selected from the group consisting of H, alkyl, halo, and haloalkyl;

R¹⁰ is selected from the group consisting of H, alkyl, halo, and haloalkyl;

R¹² and R¹³ form a cycloalkyl of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 1 1, 12, 13, or 14 carbons or R¹² and R¹³ are each independently selected from the group consisting of H, alkyl, halo, and haloalkyl; and

R¹⁴ is selected from the group consisting of H, alkyl, halo, and haloalkyl.

The method of Claim 82, wherein halo is bromo, chloro, or fluoro.

The method of Claim 74, wherein the compound has a structure of Formula (III):

wherein,

selected from the group consisting of methyl, trihalomethyl, and isopropyl; R⁸ and R⁹ form a cycloalkyl of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 1 1, 12, 13, or 14 carbons or R⁸ and R⁹ are each independently selected from the group consisting of H, alkyl, halo, and haloalkyl;

R¹⁰ is selected from the group consisting of H, alkyl, halo, and haloalkyl;

R¹² and R¹³ form a cycloalkyl of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, or 14 carbons or R¹² and R¹³ are each independently selected from the group consisting of H, alkyl, halo, and haloalkyl; and

R¹⁴ is selected from the group consisting of H, alkyl, halo, and haloalkyl. 85. The method of Claim 80, wherein the com ound has a structure of Formula (III):

wherein,

R¹⁵ is selected from the group consisting of methyl, trihalomethyl, and isopropyl;

R⁸ and R⁹ form a cycloalkyl of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, or 14 carbons or R⁸ and R⁹ are each independently selected from the group consisting of H, alkyl, halo, and haloalkyl;

R¹⁰ is selected from the group consisting of H, alkyl, halo, and haloalkyl;

R¹² and R¹³ form a cycloalkyl of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, or 14 carbons or R¹² and R¹³ are each independently selected from the group consisting of H, alkyl, halo, and haloalkyl; and

R¹⁴ is selected from the group consisting of H, alkyl, halo, and haloalkyl.

86. The method of Claim 85, wherein halo is bromo, chloro, or fluoro.

87. The method of Claim 81, wherein:

R¹² and R¹³ form a cycloalkyl moiety; and

R¹⁴ is selected from the group consisting of alkyl and haloalkyl. 88 The method of Claim 87, wherein:

R⁹ and R¹⁰ form a cycloalkyl moiety; and

R⁸ is selected from the group consisting of alkyl and haloalkyl.

89 The method of Claim 84, wherein:

R¹² and R¹³ form a cycloalkyl moiety; and

R¹⁴ is selected from the group consisting of alkyl and haloalkyl.

90 The method of Claim 89, wherein:

R⁹ and R¹⁰ form a cycloalkyl moiety; and

R⁸ is selected from the group consisting of alkyl and haloalkyl

91. A compound or pharmaceutically acceptable salt of the compound, wherein the compound is selected from the group consisting of the species of Table 1.

92. The method of Claim 75, wherein the compound is selected from the group consisting of 5- bromo-4-tert-butyl-2-methyl-phenol, 5-bromo-4-tert-butyl-2-isopropyl-phenol, 4-tert-butyl-5- chloro-2-isopropyl-phenol, 4-tert-butyl-2-isopropyl-5-trifluoromethoxy-phenol, 5-bromo-2-(tert- butyl)-4-(l, l-difluoroethyl)phenol, 5-bromo-4-tert-butyl-2-cyclopropyl-phenol, 5-bromo-2- cyclopropyl-4-trifluoromethyl-phenol, 5-bromo-2-isopropyl-4-(l-trifluoromethyl-cyclopropyl)- phenol, 5-bromo-2-isopropyl-4-(l-methyl-cyclopropyl)-phenol, 5-bromo-2-isopropyl-4-(l- pentafluoroethyl-cyclopropyl)-phenol, 5-bromo-2-isopropyl-4-pentafluoroethyl-phenol, 5-bromo-2- isopropyl-4-(2,2,3,3,3-pentafluoro-propyl)-phenol, 5-bromo-2-isopropyl-4-(2,2,2-trifluoro- l,l- dimethyl-ethyl)-phenol, 5-fiuoro-2,4-bis-( l-methyl-cyclopropyl)-phenol, 5-bromo-4-( 1-methyl- cyclopropyl)-2-(l-trifluoromethyl-cyclopropyl)-phenol, 5-fluoro-4-(l-methyl-cyclopropyl)-2-[l- (2,2,2-trifluoro-ethyl)-cyclopropyl]-phenol, 2,4-bis-(l -methyl -cyclopropyl)-5-trifluoromethoxy- phenol, 2-[l-(2,2,2-Trifluoro-ethyl)-cyclopropyl]-5-trifluoromethoxy-4-( l-trifluoromethyl-cyclo- propyl)-phenol, 2-Isopropyl-5-trifluoromethoxy-4-(l-trifluoromethyl-cyclopropyl)-phenol, and 2- cyclopropyl-5-methoxy-4-(l-trifiuoromethyl-cyclopropyl)-phenol.

93. The compound or pharmaceutically acceptable salt of Claim 91, wherein the compound is selected from the group consisting of 5-bromo-4-tert-butyl-2-methyl-phenol, 5-bromo-4-tert-butyl- 2-isopropyl-phenol, 4-tert-butyl-5-chloro-2-isopropyl-phenol, 4-tert-butyl-2-isopropyl-5-trifiuoro- methoxy-phenol, 5-bromo-2-(tert-butyl)-4-( 1 , 1 -difluoroethyl)phenol, 5-bromo-4-tert-butyl-2- cyclopropyl-phenol, 5-bromo-2-cyclopropyl-4-trifluoromethyl-phenol, 5-bromo-2-isopropyl-4-( 1- trifluoromethyl-cyclopropyl)-phenol, 5-bromo-2-isopropyl-4-(l -methyl -cyclopropyl)-phenol, 5- bromo-2-isopropyl-4- ( 1 -pentafluoroethyl-cyclopropyl)-phenol, 5-bromo-2-isopropyl-4-pentafluoro- ethyl-phenol, 5-bromo-2-isopropyl-4-(2,2,3,3,3-pentafluoro-propyl)-phenol, 5-bromo-2-isopropyl-4- (2,2,2-trifluoro- 1 , 1 -dimethyl-ethyl )-phenol, 5-fluoro-2,4-bis-( 1 -methyl-cyclopropyl)-phenol, 5- bromo-4-(l-methyl-cyclopropyl)-2-(l-trifluoromethyl-cyclopropyl)-phenol, 5-fluoro-4-( l-methyl- cyclopropyl)-2-[l-(2,2,2-trifluoro-ethyl)-cyclopropyl]-phenol, 2,4-bis-( l-methyl-cyclopropyl)-5- trifluoromethoxy-phenol, 2- [ 1 -(2,2,2-Trifluoro-ethyl)-cyclopropyl] -5-trifluoromethoxy-4-( 1 -tri- fluoromethyl-cyclopropyl)-phenol, 2-Isopropyl-5-trifluoromethoxy-4-(l-trifluoromethyl-cyclo- propyl)-phenol, and 2-cyclopropyl-5-methoxy-4-(l-trifluoromethyl-cyclopropyl)- phenol.

94. The method of any one of Claims 73-90 or 92 wherein the compound is deuterated.

95. The compound or pharmaceutically acceptable salt of Claim 91 or 93, wherein the compound is deuterated.

96. A method of treating a neurological or an inflammatory condition comprising administering a therapeutically effective amount of a compound or pharmaceutically acceptable salt of the compound, wherein the compound has a structure of Formula (IV):

R is selected from the group consisting of an ester, a carbonate, a phosphate, a carbamate, a sulfamate, and an acylmethylester; R² is selected from the group consisting of alkyl, haloalkyl, and cycloalkyl, wherein the alkyl or haloalkyl is optionally substituted with one or more cycloalkyl substituents;

R⁴ is selected from the group consisting of alkyl, haloalkyl, and cycloalkyl, wherein the alkyl or haloalkyl is optionally substituted with one or more cycloalkyl substituents, and wherein R⁴ is not methyl; and

R³ is selected from the group consisting of halo, and alkoxy, wherein the alkoxy may be optionally substituted with one or more substituents independently selected from the group consisting of alkyl and halo.

97. The method of Claim 96, wherein the compound has a structure of Formula (V):

wherein D¹ is alkyl, aryl, cycloalkyl, heterocycloalkyl, heteroalkyl, heteroaryl, heteroaralkyl, carbonylalkyl, or phosphonooxyalkyl, optionally substituted with one or more substituents selected from the group consisting of alkyl, carboxylate, heteroalkyl, monocyclic ring, bicyclic ring, and hydroxyl moieties.

The method of Claim 97, wherein the compound has a structure of Formula (VI):

D² and D³ together with the carbon atom to which they are bonded form a cycloalkyl or cycloheteroalkyl ring, or alternatively D² and D³ are each independently selected from the group consisting of hydrogen, alkyl, and heteroalkyl,;

2 3

A, Y, and one of D or D together with the atoms to which they are bonded to form a cycloheteroalkyl ring, or alternatively A is selected from the group consisting of hydrogen, phosphono, alkyl, aryl, arylalkyl, heteroalkyl, heteroaryl, and heteroarylalkyl;

X is selected from the group consisting of— ND⁴— ,— O— ,— CH₂— , and— S— ;

Y is selected from the group consisting of— O— and— ND⁴— ;

n is an integer from 1 to 5; and

D⁴ is selected from the group consisting of hydrogen, alkyl, and arylalkyl.

2 3

99. The method of Claim 98, wherein D and D are each hydrogen, X is— CH₂— , Y is— O— , A is phosphono, and n=l.

100. The method of Claim 96, wherein R¹ is selected from the group consisting of -P-(0)(OD⁵)₂,

CH₃

-CH₂-0-P-(0)(OD⁵)₂, -(CH₂)₂-0-P-(0)(OD⁵)₂, and -CH₂-0-P-(0)(OD⁵)₂, and further wherein Ό³ is H or a pharmaceutically acceptable cation.

101. The method of Claim 100, wherein the pharmaceutically acceptable cation is selected from the group consisting of Li⁺, Na⁺, and K⁺. od of Claim 96, wherein R is selected from the group consisting of

103. The method of Claim 96, wherein R is selected from the group consisting of

-CO^HCH₂(CH₂)_nCH₃, -CON(CH₃)₂, -CON(C₂H₅)₂, -CON(CH(CH₃)₂)₂, -CONNH₂

CH₃

104. The method of Claim 24, wherein R¹ is

105. The method of any one of the previous claims wherein:

alkyl is selected from the group consisting of methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, .vet-butyl, pentanyl, isopentanyl, and neopentanyl;

haloalkyl is selected from the group consisting of fluoromethyl, 1-fluoroethyl, 2-fluoroethyl, 1- fluoropropyl, 2-fiuoropropyl, 3-fluoropropyl, chloromethyl, 1-chloroethyl, 2-chloroethyl, 1- chloropropyl, 2-chloropropyl, 3-chloropropyl, bromomethyl, 1-bromoethyl, 2-bromoethyl, 1- bromopropyl, 2-bromopropyl, and 3-bromopropyl; and cycloalkyl is selected from the group consisting of cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.

106. A method of treating a neurological or an inflammatory condition comprising administering a therapeutically effective amount of a compound or pharmaceutically acceptable salt of the compound, wherein the compound has a structure of Formula I):

wherein:

R² is selected from the group consisting of alkyl, haloalkyl, and cycloalkyl, wherein the alkyl or haloalkyl is optionally substituted with one or more cycloalkykl substituents;

R⁴ is selected from the group consisting of H, halo, alkyl, alkoxy, haloalkyl, haloalkoxy and cycloalkyl, wherein alkyl or haloalkyl is optionally substituted with one or more cycloalkyl substituents, wherein alkoxy alkyl hydrogens may be optionally substituted with one or more substituents independently selected from the group consisting of alkyl and halo, and wherein R⁴ is not methyl;

R⁵ is selected from the group consisting of alkyl, haloalkyl, cycloalkyl, halo, and alkoxy, wherein the alkoxy may be optionally substituted with one or more substituents independently selected from the group consisting of alkyl and haloalkyl; and

R⁶ is halo.

107. The method of Claim 106, wherein each of R², R⁴, and R³ has between one and five carbons.

108. The method of Claim 106, wherein the condition is epilepsy, seizures, or convulsions.

109. The method of Claim 106, wherein the condition is neuropathic pain or fibromyalgia.

110. The method of Claim 106, wherein the condition is a psychological disorder.

11 1. The method of Claim 1 10, wherein the psychological disorder is anxiety, mania, bipolar disorder, or depression.

112. The method of Claim 106, wherein the condition is Alzheimer's Disease, Huntington's Disease, Multiple Sclerosis, Parkinson's disease, Tourette's Syndrome, tinnitus, and tremors.

113. The method of Claim 107, wherein R² and R⁴ are not identical.

114. The method of Claim 107 wherein the compound has a structure of Formula (II):

wherein:

R⁵ is halo;

R⁶ is halo;

R⁸, R⁹, and R^{l f)} are each independently selected from the group consisting of H, alkyl, halo, haloalkyl, cycloalkyl comprising R⁸ and R⁹, and cycloalkyl comprising R⁹ and R¹⁰; and

R¹², R¹³, and R¹⁴ are each independently selected from the group consisting of H, alkyl, halo, haloalkyl, cycloalkyl comprising R¹² and R¹³, and cycloalkyl comprising R¹³ and R¹⁴.

115. The method of Claim 1 13, wherein the compound has a structure of Formula (II), wherein:

R⁵ is halo;

R⁶ is halo;

. R⁸, R⁹, and R¹⁰ are each independently selected from the group consisting of H, alkyl, halo, haloalkyl, cycloalkyl comprising R⁸ and R⁹, and cycloalkyl comprising R⁹ and R¹⁰; and R¹², R¹³, and R'⁴ are each independently selected from the group consisting of H, alkyl, halo, haloalkyl, cycloalkyl comprising R and R , and cycloalkyl comprising

1 16. The method of Claim 1 14, wherein halo is Br, CI, or F.

The method of Claim 107, wherein the compound has a structure of Formula (III):

R⁶ is halo;

R⁸, R⁹, and R¹⁰ are each independently selected from the group consisting of H, alkyl, halo, haloalkyl, cycloalkyl comprising R⁸ and R⁹, and cycloalkyl comprising R⁹ and R¹⁰;

R'^z, R^IJ, and R¹⁴ are each independently selected from the group consisting of H, alkyl, halo, haloalkyl, cycloalkyl comprising R¹⁷ and R¹³, and cycloalkyl comprising R¹³ and R¹⁴; and

R¹³ is selected from the group consisting of methyl, trihalomethyl, and isopropyl.

1 18. The method of Claim 113, wherein the compound has a structure of Formula (111) and wherein:

R'^J is selected from the group consisting of methyl, trihalomethyl, and isopropyl;

R⁸, R^y, and R¹⁰ are each independently selected from the group consisting of H, alkyl, halo, haloalkyl, cycloalkyl comprising R⁸ and R⁹, and cycloalkyl comprising R⁹ and R¹⁰; and

R¹², R¹³, and R¹⁴ are each independently selected from the group consisting of t

, 14

haloalkyl, cycloalkyl comprising R¹² and R¹³, and cycloalkyl comprising R¹³ and R

119. The method of Claim 1 17, wherein halo is bromo, chloro, or fluoro.

120. The method of Claim 114, wherein:

R¹² and R¹³ form a cycloalkyl moiety; and

R¹⁴ is selected from the group consisting of alkyl and haloalkyl.

121. The method of Claim 120, wherein:

R⁹ and R¹⁰ form a cycloalkyl moiety; and

R is selected from the group consisting of alkyl and haloalkyl.

The method of Claim 117, wherein:

R and R form a cycloalkyl moiety; and

R¹⁴ is selected from the group consisting of alkyl and haloalkyl.

The method of Claim 122, wherein:

R⁹ and R¹⁰ form a cycloalkyl moiety; and

R⁸ is selected from the group consisting of alkyl and haloalkyl.

124. The method of Claim 108, wherein the compound is selected from the group consisting of the species of Table 1.

125. A compound or pharmaceutically acceptable salt of the compound, wherein the compound is selected from the group consisting of the species of Table 1.

126. The method of Claim 106, wherein the compound has a structure of Formula (IV):

wherein:

R² is selected from the group consisting of alkyl, haloalkyl, and cycloalkyl;

R⁶ is halo;

R⁸, R⁹, and R¹⁰ are each independently selected from the group consisting of H, alkyl, haloalkyl, cycloalkyl comprising R⁸ and R⁹, and cycloalkyl comprising R⁹ and R¹⁰; and

R¹², R¹³, and R¹⁴ are each independently selected from the group consisting of H, alkyl, haloalkyl, cycloalkyl comprising R¹² and R¹³, and cycloalkyl comprising R¹³ and R¹⁴.

127. The method of Claim 126, wherein halo is chloro, bromo, or fluoro.

128. The method of Claim 127, wherein the halo is fluoro.

129. The method of Claim 106, wherein the compound has a structure of Formula (V):

wherein:

R³ is selected from the group consisting of alkyl, haloalkyl, and cycloalkyl;

R⁶ is halo;

R¹² and R¹³ form a cycloalkyl of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 1 1, 12, 13, or 14 carbons or R¹² and R¹³ are each independently selected from the group consisting of H, alkyl, and haloalkyl;

R¹⁴ is selected from the group consisting of H, alkyl, and haloalkyl;

R¹⁵ and R¹⁶ form a cycloalkyl of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 1 1, 12, 13, or 14 carbons or R¹⁵ and R¹⁶ are each independently selected from the group consisting of H, alkyl, and haloalkyl; and R¹⁷ is selected from the group consisting of H, alkyl, and haloalkyl.

130. The method of Claim 129, wherein halo is chloro, bromo, or fluoro.

131. The method of Claim 130, wherein the halo is fiuoro.

132. The method of Claim 126, wherein:

R¹² and R¹³ form a cycloalkyl moiety; and

R¹⁴ is selected from the group consisting of alkyl and haloalkyl.

133. The method of Claim 129, wherein:

R¹² and R¹³ form a cycloalkyl moiety;

R¹³ and R¹⁶ form a cycloalkyl moiety; and

R¹⁴ and R¹⁷ are each independently selected from the group consisting of alkyl and haloalkyl.

134. The method of Claim 129, wherein the compound has a structure of Formula (V), and wherein:

R³ is selected from the group consisting of methyl and isopropyl;

R¹² is selected from the group consisting of H, halo, methyl, and cycloalkyl comprising R¹³; R¹³ is selected from the group consisting of H, halo, methyl, trihalomethyl, and cycloalkyl comprising R¹²;

R¹⁴ is selected from the group consisting of halo, methyl, trihalomethyl and pentahaloethyl;

R¹³ is selected from the group consisting of H, methyl, and trihalomethyl.

R¹⁶ is selected from the group consisting of H and cycloalkyl comprising R¹⁷; and

R¹⁷ is selected from the group consisting of H, methyl, and cycloalkyl comprising R¹⁶.

135. The method of Claim 134, wherein the halo is chloro, bromo, or fiuoro.

136. The method of Claim 135, wherein the halo is fiuoro.

137. The method of Claim 135, wherein the compound is selected from the group consisting of the species of Table 2.

138. A compound or pharmaceutically acceptable salt of the compound, wherein the compound has a structure of Formula (V)

wherein:

R³ is selected from the group consisting of methyl and isopropyl;

R¹² is selected from the group consisting of H, halo, methyl, and cycloalkyl comprising R¹³; R¹³ is selected from the group consisting of H, halo, methyl, trihalomethyl, and cycloalkyl comprising R¹²;

R¹⁴ is selected from the group consisting of halo, methyl, trihalomethyl and pentahaloethyl;

R¹⁵ is selected from the group consisting of H, methyl, and trihalomethyl.

R¹⁶ is selected from the group consisting of H and cycloalkyl comprising R¹⁷; and

17 16

R is selected from the group consisting of H, methyl, and cycloalkyl comprising R .

139. The compound or pharmaceutically acceptable salt of Claim 138, wherein the compound is selected from the group consisting of the species of Table 2.

140. The method of Claim 106, wherein:

R² is selected from the group consisting of alkyl, haloalkyl, and cycloalkyl; and

R⁴ is halo.

141. The method of Claim 140, wherein:

R⁴ is selected from the group consisting of Br, CI, and F.

142. The method of Claim 141, wherein:

R² is alkyl; and

R⁵ is alkyl having two or more carbons.

143. The method of Claim 142, wherein the compound is selected from the group consisting of 4- bromo-2-fiuoro-3-isopropyl-6-methyl-phenol, 4-chloro-2-fluoro-3-isopropyl-6-methyl-phenol, 2,4- difiuoro-3-isopropyl-6-methyl-phenol, 4-bromo-2-fiuoro-3-isopropyl-6-trifluoromethyl-phenol, 4- bromo-2-fiuoro-6-trifiuoromethyl-3-(2,2,2-trifluoro- l-methyl-ethyl)-phenol, 4-bromo-6-cyclo propyl-2-fluoro-3-(2,2,2-trifluoro-l-methyl-ethyl)-phenol, 4-bromo-3-cyclopropyl-2-fluoro-6- methyl-phenol, 4-bromo-3-cyclopropyl-2-fiuoro-6-trifluoromethyl-phenol, 4-bromo-3,6-dicyclo propyl -2- fiuoro-phenol , 4-bromo-2-chloro-3 -isopropyl-6-methyl-phenol, 2-fluoro-3-i sopropyl-6- methyl-4-trifluoromethoxy-phenol , 2-bromo-3-isopropyl-6-methyl-4-trifluoro-methoxy-phenol , 2- chloro-3-isopropyl-6-methyl-4-trifiuoromethoxy-phenol, 4-tert-butoxy-2-fiuoro-3-isopropyl-6- methyl -phenol, 2-bromo-4-tert-butoxy-3-isopropyl-6- methyl-phenol, 4-bromo-3-(2,2-difluoro- 1 - methyl-ethyl)-2-fiuoro-6-isopropyl-phenol, 4-bromo-2-fiuoro-6-iso-propyl-3-pentafiuoroethyl- phenol, 4-bromo-2-fluoro-6-isopropyl-3-(2,2,2-trifiuoro-ethyl)-phenol, 4-bromo-3-ethyl-2-fiuoro-6- (2,2,2-trifluoro- 1 , 1 -dimethyl-ethyl)-phenol, 4-bromo-2-fluoro-6-isopropyl-3-(2,2,2-trifiuoro- 1 - trifiuoromethyl-ethyl)-phenol, 4-bromo-2-fluoro-6-iso-propyl-3-(2,2,3,3,3-pentafluoro-propyl)- phenol, 2-fluoro-6-isopropyl-3-(2,2,3,3,3-pentafluoro-propyl)-4-trifluoro-methoxy-phenol, 2-fiuoro- 4-isopropoxy-6-isopropyl-3-(2,2,2-trifluoro-ethyl)-phenol, 2-fluoro-6-isopropyl-4-methoxy-3-(2,2,2- trifluoro-ethyl)-phenol, 3-ethyl-2-fiuoro-6-(2,2,2-trifluoro- 1 , 1 -dimethyl-ethyl)-4-trifluoro methoxy- phenol, 2-fluoro-6-isopropyl-4-methoxy-3-(2,2,2-trifluoro-ethyl)-phenol, 4-tert-butoxy-3-(2,2- difiuoro- 1 -methyl -ethyl)-2-fiuoro-6-isopropyl-phenol, 2-bromo-3-isopropyl-4-trifluorometh oxy-6- (2,2,2-trifluoro- l-methyl-ethyl)-phenol, 3-ethyl-2-fluoro-6-(2,2,2-trifluoro-ethy)-4-trifluoro methoxy-phenol, 4-tert-butoxy-3-ethyl-2-fiuoro-6-(2,2,2-trifluoro-ethyl)-phenol, and 3-ethyl-2- fluoro-4-isopropoxy-6-(2,2,2-trifluoro-ethyl)-phenol.

144. The method of Claim 108, wherein the compound is selected from the group consisting of 4- bromo-2-fluoro-3-isopropyl-6-methyl-phenol, 4-chloro-2-fluoro-3-isopropyl-6-methyl-phenol, 2,4- difiuoro-3-isopropyl-6-methyl-phenol, 4-bromo-2-fluoro-3-isopropyl-6-trifluoromethyl-phenol, 4- bromo-2-fluoro-6-trifluoromethyl-3-(2,2,2-trifluoro- l-methyl-ethyl)-phenol, 4-bromo-6-cyclo propyl -2-fluoro-3-(2,2,2-trifiuoro- 1 -methyl -ethyl)-phenol, 4-bromo-3-cyclopropyl-2-fluoro-6- methyl-phenol, 4-bromo-3,6-dicyclopropyl-2-fluoro-phenol, 2,4-dibromo-3-isopropyl-6-methyl- phenol, 4-bromo-2-chloro-3-isopropyl-6-methyl-phenol, 2,4-dichloro-3-isopropyl-6-methyl-phenol, 2,4-dibromo-3-isopropyl-6-(2,2,2-trifluoro- 1 -methyl-ethyl )-phenol, 4-bromo-3-( 1 , 1 -difluoroethyl)- 2-fluoro-6-isopropyl-phenol, 2-fluoro-6-isopropyl-3-(2,2,3,3,3-pentafluoro-propyl)-4-trifluorometh oxy-phenol, 2-fluoro-4-isopropoxy-6-isopropyl-3-(2,2,2-trifluoroethyl)-phenol, 2-fluoro-6- isopropyl-4-methoxy-3-(2,2,2-trifluoroethyl)-phenol, 4-tert-butoxy-3-ethyl-2-fluoro-6-(2,2,2-tri fiuoroethyl)-phenol, 2-fluoro-3-isopropyl-6-methyl-4-trifluoromethoxy-phenol, 2-bromo-3- isopropyl-6-methyl-4-trifluoromethoxy-phenol, and 2-chloro-3-isopropyl-6-methyl-4-trifluoro methoxy-phenol.

The method of Claim 106, wherein the compound has the structure of Formula (VI):

wherein:

R is selected from the group consisting of alkyl, haloalkyl, and cycloalkyl;

R⁴ is selected from the group consisting of Br, CI, and F;

R⁶ is halo; and

R⁸, R⁹ and R¹⁰ are each independently selected from the group consisting of H, alkyl, and haloalkyl.

The method of Claim 106, wherein the compound has the structure of Formula (VII):

wherein:

R is selected from the group consisting of alkyl, haloalkyl, and cycloalkyl;

R³ is selected from the group consisting of alkyl, haloalkyl, and cycloalkyl;

R⁶ is halo; and

R₇ is selected from the group consisting of alkyl and haloalkyl.

147. The method of Claim 145, wherein:

R² is selected from the group consisting of alkyl, haloalkyl, and cycloalkyl;

R³ is selected from the group consisting of alkyl, haloalkyl, and cycloalkyl; and

R₇ is alkyl.

The method of Claim 146, wherein the compound has the structure of Formula (VIII):

wherein:

R² is selected from the group consisting of alkyl, haloalkyl, and cycloalkyl;

R³ is selected from the group consisting of alkyl, haloalkyl, and cycloalkyl; and

R⁶ is halo.

149. The method of Claim 148, wherein:

R² is selected from the group consisting of alkyl and cycloalkyl; and

R⁵ is selected from the group consisting of alkyl and cycloalkyl.

150. A compound or pharmaceutically acceptable salt of the compound, wherein the compound has the structure of Formula (X):

wherein:

R² is selected from the group consisting of methyl, cycloalkyl, and -CF₃;

R⁴ is halo;

R³ is selected from the group consisting of fluoroalkyl and a three, four, or five carbon cycloalkyl; R⁶ is halo; and

R⁴ and R⁶ are not both Br or both CI.

151. The compound or pharmaceutically acceptable salt of Claim 150, wherein:

R⁴ is selected from the group consisting of Br, CI, and F.

152. A compound or pharmaceutically acceptable salt of the compound, wherein the compound has the structure of Formula (XI):

(XI)

wherein:

R² and R⁵ are each independently selected from the group consisting of alkyl and cycloalkyl, wherein at least one of R² and R³ is cycloalkyl;

R⁶ is halo; and

R₇ is selected from the group consisting of isopropyl, rerr-butyl, and haloalkyl.

153. The compound or pharmaceutically acceptable salt of Claim 152, wherein:

R₇ is selected from the group consisting of isopropyl and tert-butyl.

154. The compound or pharmaceutically acceptable salt of Claim 152, wherein:

R is selected from the group consisting of alkyl, and cycloalkyl;

R³ is selected from the group consisting of alkyl, and cycloalkyl; and

R⁷ is trifiuoromethyl.

155. The method of Claim 109, wherein:

R² and R⁵ are each independently selected from the group consisting of methyl, isopropyl, and rm-butyl; and

R⁴ and R⁶ are each independently selected from the group consisting of Br, CI, and F.

156. The compound or pharmaceutically acceptable salt of Claim 151, wherein the compound is selected from the group consisting of 4-bromo-2-fluoro-3-isopropyl-6-methyl-phenol, 4-chloro-2- fiuoro-3-isopropyl-6-methyl-phenol, 2,4-difluoro-3-isopropyl-6-methyl-phenol, 4-bromo-2-fluoro-3- isopropyl-6-trifluoromethyl-phenol, 4-bromo-2-fluoro-6-trifluoromethyl-3-(2,2,2-trifluoro-l-methyl- ethyl)-phenol, 4-bromo-6-cyclopropyl-2-fluoro-3-(2,2,2-trifluoro-l-methyl-ethyl)-phenol, 4-bromo-

3- cyclopropyl-2-fluoro-6-methyl-phenol, 4-bromo-3-cyclopropyl-2-fluoro-6-trifluoromethyl-phenol,

4- bromo-3,6-dicyclopropyl-2-fiuoro-phenol, 4-bromo-2-chloro-3-isopropyl-6-methyl-phenol, 2- fiuoro-3-isopropyl-6-methyl-4-trifiuoromethoxy-phenol, 2-bromo-3-isopropyl-6-methyl-4- trifiuoromethoxy-phenol, 2-chloro-3-isopropyl-6-methyl-4-trifluoromethoxy-phenol, 4-tert-butoxy-

2- fiuoro-3-isopropyl-6-methyl-phenol, 2-bromo-4-tert-butoxy-3-isopropyl-6-methyl-phenol, 4- bromo-3-(2,2-difluoro- l-methyl-ethyl)-2-fluoro-6-isopropyl-phenol, 4-bromo-2-fiuoro-6-iso-propyl-

3- pentafluoroethyl-phenol, 4-bromo-2-fluoro-6-isopropyl-3-(2,2,2-trifluoro-ethyl)-phenol, 4-bromo- 3-ethyl-2-fluoro-6-(2,2,2-trifluoro- 1 , l-dimethyl-ethyl)-phenol, 4-bromo-2-fiuoro-6-iso-propyl-3- (2,2,2-trifluoro- l-trifiuoromethyl-ethyl)-phenol, 4-bromo-2-fluoro-6-isopropyl-3-(2,2,3, 3,3- pentafiuoro-propyl)-phenol, 2-fluoro-6-isopropyl-3-(2,2,3,3,3-pentafluoro-propyl)-4-trifluoro- methoxy-phenol, 2-fluoro-4-isopropoxy-6-isopropyl-3-(2,2,2-trifluoro-ethyl)-phenol, 2-fiuoro-6- isopropyl-4-methoxy-3-(2,2,2-trifluoro-ethyl)-phenol, 3-ethyl-2-fluoro-6-(2,2,2-trifluoro- 1 , 1 -di- methyl-ethyl)-4-trifluoromethoxy-phenol, 2-fluoro-6-isopropyl-4-methoxy-3-(2,2,2-trifluoro-ethyl)- phenol, 4-tert-butoxy-3-(2,2-difluoro-l -methyl -ethyl )-2-fiuoro-6-isopropyl -phenol, 2-bromo-3- isopropyl-4-trifluoromethoxy-6-(2,2,2-trifluoro- l-methyl-ethyl)-phenol, 3-ethyl-2-fluoro-6-(2,2,2- trifluoro-ethyl)-4-trifluoromethoxy-phenol, 4-tert-butoxy-3-ethyl-2-fluoro-6-(2,2,2-trifiuoro-ethyl)- phenol, and 3-ethyl-2-fluoro-4-isopropoxy-6-(2,2,2-trifluoro-ethyl)-phenol.

157. The compound or pharmaceutically acceptable salt of Claim 156, wherein the compound is selected from the group consisting of 4-bromo-2-fluoro-3-isopropyl-6-methyl-phenol, 4-chloro-2- fluoro-3-isopropyl-6-methyl-phenol, 2,4-difluoro-3-isopropyl-6-methyl-phenol, 4-bromo-2-fluoro-3- isopropyl-6-trifluoromethyl-phenol, 4-bromo-2-fluoro-6-trifiuoromethyl-3-(2,2,2-trifluoro-l-methyl- ethyl)-phenol, 4-bromo-6-cyclopropyl-2-fluoro-3-(2,2,2-trifiuoro-l-methyl-ethyl)-phenol, 4-bromo- 3-cyclopropyl-2-fluoro-6-methyl-phenol, 4-bromo-3,6-dicyclopropyl-2-fluoro-phenol, 4-bromo-2- chloro-3-isopropyl-6-methyl-phenol, 2,4-dibromo-3-isopropyl-6-(2,2,2-trifiuoro-l-methyl-ethyl)- phenol, 4-bromo-3-(l, l-difluoroethyl)-2-fluoro-6-isopropyl-phenol, 2-fluoro-6-isopropyl-3- (2,2,3,3,3-pentafluoro-propyl)-4-trifluoromethoxy-phenol, 2-fluoro-4-isopropoxy-6-isopropyl-3- (2,2,2-trifluoroethyl)-phenol, 2-fluoro-6-isopropyl-4-methoxy-3-(2,2,2-trifluoroethyl)-phenol, 4-tert- butoxy-3-ethyl-2-fluoro-6-(2,2,2-trifluoro-ethyl)-phenol, 2-fiuoro-3-isopropyl-6-methyl-4-trifluoro- methoxy-phenol, 2-bromo-3-isopropyl-6-methyl-4-trifluoromethoxy-phenol, and 2-chloro-3- isopropyl-6-methyl-4-trifluoromethoxy-phenol.

158. The method of Claim 108, wherein the compound is selected from the group consisting of 4- tert-butyl-2-fluoro-6-isopropyl-3-methyl-phenol, 4-tert-butyl-2-fluoro-6-isopropyl-3-trifluoromethyl- phenol, 2-fluoro-6-isopropyl-3-methyl-4-(2,2,2-trifluoro- 1 , 1 -dimethyl-ethyl)-phenol, 2-bromo-6- isopropyl-3-methyl-4-trifluoromethyl-phenol, 4-tert-butyl-6-cyclopropyl-2-fluoro-3-trifluoromethyl- phenol, 2-fluoro-6-isopropyl-3-methyl-4-( 1 -methyl -cyclopropyl)-phenol, 2-fluoro-6-isopropyl-3- methyl-4-[l-(2,2,2-trifiuoro-ethyl)-cyclopropyl]-phenol, 2-fluoro-6-isopropyl-3-methyl-4-(l-penta- fluoroethyl-cyclopropyl)-phenol, 2-fluoro-3-methyl-4-(2,2,3,3,3-pentafluoro-propyl)-6-(2,2,2-tri- fluoro- l-methyl-ethyl)-phenol, 2-fiuoro-3-methyl-4-pentafluoroethyl-6-(2,2,2-trifluoro-l-methyl- ethyl)-phenol, 3-cyclopropyl-2-fluoro-4-(2,2,2-trifluoro- 1 , 1 -dimethyl-ethyl)-6- ( 1 -trifluoromethyl- cyclopropyl)-phenol, 2-fluoro-3-methyl-4,6-bis-( l-methyl-cyclopropyl)- phenol, 2-fluoro-3-methyl- 4-(l-methyl-cyclopropyl)-6-(l-trifluoromethyl-cyclopropyl)-phenol, 2-fluoro-3-methyl-4,6-bis-(l- trifluoromethyl-cyclopropyO-phenol, and 2-fiuoro-3-methyl-6-( 1 -methyl-cyclopropyl)-4-(2,2,2- trifluoro- 1 , l-dimethyl-ethyl)-phenol.

159. The compound or pharmaceutically acceptable salt of Claim 139, wherein the compound is selected from the group consisting of 4-tert-butyl-2-fluoro-6-isopropyl-3-methyl-phenol, 4-tert- butyl-2-fluoro-6-isopropyl-3-trifluoromethyl-phenol, 2-fluoro-6-isopropyl-3-methyl-4-(2,2,2-tri- fluoro- l,l-dimethyl-ethyl)-phenol, 2-bromo-6-isopropyl-3-methyl-4-trifiuoromethyl-phenol, 4-tert- butyl-6-cyclopropyl-2-fluoro-3-trifluoromethyl-phenol, 2-fluoro-6-isopropyl-3-methyl-4-( l-methyl- cyclopropyl)-phenol, 2-fluoro-6-isopropyl-3-methyl-4-[ 1 -(2,2,2-trifluoro-ethyl)-cyclopropyl] - phenol , 2-fluoro-6-isopropyl-3 -methyl -4-( 1 -pentafluoroethyl-cyclopropyl)-phenol, 2-fluoro-3- methyl-4-(2,2,3,3,3-pentafluoro-propyl)-6-(2,2,2-trifluoro-l-methyl-ethyl)-phenol, 2-fluoro-3- methyl-4-pentafluoroethyl-6-(2,2,2-trifiuoro- 1 -methyl -ethyl)-phenol, 3-cyclopropyl-2-fluoro-4- (2,2,2-trifluoro- 1 , l-dimethyl-ethyl)-6-( 1 -trifluoromethyl-cyclopropyl)-phenol, 2-fluoro-3-methyl- 4,6-bis-(l-methyl-cyclopropyl)-phenol, 2-fluoro-3-methyl-4-( l-methyl-cyclopropyl)-6-(l-trifluoro- methyl-cyclopropyl)-phenol, 2-fluoro-3-methyl-4,6-bis-(l-trifluoromethyl-cyclopropyl)-phenol, and

2- fluoro-3-methyl-6- ( 1 -methyl-cyclopropyl)-4-(2,2,2-trifluoro- 1 , 1 -dimethyl-ethyl )-phenol .

160. The method of Claim 108, wherein the compound is selected from the group consisting of 3- bromo-4-tert-butyl-2-fluoro-6-isopropyl-phenol, 4-tert-butyl-3-chloro-2-fluoro-6-isopropyl-phenol, 4-tert-butyl-2,3-difluoro-6-isopropyl -phenol, 3-bromo-6-cyclopropyl-2-fluoro-4-(2,2,2-trifluoro- 1,1- dimethyl-ethyl)-phenol, 3-bromo-2-fluoro-6-isopropyl-4-trifluoromethyl-phenol, 3-bromo-2-fluoro- 6-isopropyl-4-(l-methyl-cyclopropyl)-phenol, 3-bromo-2-fluoro-6-isopropyl-4-(l-trifluoromethyl- cyclopropyl)-phenol, 3-bromo-6-cyclopropyl-2-fluoro-4-(l-trifluoromethyl-cyclopropyl)-phenol, 4- tert-butyl-2-fluoro-6-isopropyl-3-trifluoromethoxy-phenol, 3-tert-butoxy-2-fluoro-6-isopropyl-4- trifluoromethyl-phenol, 2-fluoro-6-isopropyl-4-(l-methyl-cyclopropyl)-3-trifluoromethoxy-phenol,

3- bromo-2-fluoro-4-pentafluoroethyl-6-(2,2,2-trifluoro-l-methyl-ethyl)-phenol, 3-bromo-2-fiuoro-4- pentafluoroethyl-6-(2,2,2-trifluoro-l-methyl-ethyl)-phenol, 3-bromo-2-fiuoro-6-isopropyl-4- (2,2,3,3,3-pentafluoro-propyl)-phenol, 3-bromo-2-fluoro-4-(2,2,2-trifluoro- 1 , 1 -dimethyl-ethyl)-6-( 1 - trifluoromethyl-cyclopropyl)-phenol, 3-bromo-2-fluoro-4-( 1 -methyl -cyclopropyl)-6-( 1 -trifluoro- methyl-cyclopropyl)-phenol, 3-bromo-2-fluoro-6-(l -methyl -cyclopropyl)-4-(l-trifluoromethyl- cyclopropyl)-phenol, 3-bromo-2-fluoro-4,6-bis-( 1 -trifluoromethyl-cyclopropyl)-phenol, 3-bromo-2- fluoro-6-( 1 -methyl-cyclopropyl)-4-(2,2,2-trifluoro- 1 , 1 -dimethyl-ethyl)-phenol, and 3-bromo-2- fluoro-4-(2,2,2-trifluoro- 1 , 1 -dimethyl-ethyl)-6-( 1 -trifluoromethyl-cyclopropyl)-phenol.

161. The compound or pharmaceutically acceptable salt of Claim 125, wherein the compound is selected from the group consisting of 3-bromo-4-tert-butyl-2-fluoro-6-isopropyl-phenol, 4-tert- butyl-3-chloro-2-fluoro-6-isopropyl-phenol, 4-tert-butyl-2,3-difluoro-6-isopropyl-phenol, 3-bromo- 6-cyclopropyl-2-fluoro-4-(2,2,2-trifluoro-l,l-dimethyl-ethyl)-phenol, 3-bromo-2-fluoro-6-iso- propyl-4-trifluoromethyl-phenol, 3-bromo-2-fluoro-6-isopropyl-4-(l -methyl -cyclopropyl)-phenol, 3- bromo-2-fluoro-6-isopropyl-4-( 1 -trifiuoromethyl-cyclopropyl)-phenol, 3-bromo-6-cyclopropyl-2- fluoro-4-(l-trifluoromethyl-cyclopropyl)-phenol, 4-tert-butyl-2-fluoro-6-isopropyl-3-trifluoro- methoxy-phenol, 3-tert-butoxy-2-fluoro-6-isopropyl-4-trifluoromethyl-phenol, 2-fluoro-6-isopropyl-

4- (l -methyl -cyclopropyl)-3-trifluoromethoxy-phenol, 3-bromo-2-fluoro-4-pentafluoroethyl-6-(2,2,2- trifluoro-1 -methyl -ethyl )-phenol, 3-bromo-2-fluoro-4-pentafluoroethyl-6-(2,2,2-trifluoro-l-methyl- ethyl)-phenol, 3-bromo-2-fluoro-6-isopropyl-4-(2,2,3,3,3-pentafluoro-propyl)-phenol, 3-bromo-2- fluoro-4-(2,2,2-trifluoro- l,l-dimethyl-ethyl)-6-( l-trifluoromethyl-cyclopropyl)-phenol, 3-bromo-2- fluoro-4-( 1 -methyl-cyclopropyl)-6-( 1 -trifluoromethyl-cyclopropyl)-phenol, 3-bromo-2-fiuoro-6-( 1 - methyl-cyclopropyl)-4-( l-trifluoromethyl-cyclopropyl)-phenol, 3-bromo-2-fiuoro-4,6-bis-(l- trifluoromethyl-cyclopropyl)-phenol, 3-bromo-2-fiuoro-6-(l-methyl-cyclopropyl)-4-(2,2,2-trifluoro- 1 , 1 -dimethyl -ethyl)-phenol , and 3-bromo-2-fluoro-4-(2,2,2-trifluoro- 1 , 1 -dimethyl-ethyl)-6-( 1 - trifluoromethyl-cyclopropyl)-phenol.

162. A compound or pharmaceutically acceptable salt of the compound, wherein the compound has the structure of Formula (IX):

(IX)

wherein:

R² is selected from the group consisting of haloalkyl and cycloalkyl;

is selected from the group consisting of haloalkyl and cycloalkyl; and

R⁶ is halo.

163. The method of any one of Claims 106-124, 126-137, 140-148, 155, 158, or 160, wherein the compound is deuterated.

164. The compound or pharmaceutically acceptable salt of any one of Claims 125, 138, 139, 149- 154, or 156-161 wherein the compound is deuterated.

165. A method of treating a neurological or an inflammatory condition comprising administering a therapeutically effective amount of a compound or pharmaceutically acceptable salt of the compound, wherein the compound has a structure of Formula (XII):

wherein:

R¹ is selected from the group consisting of an ester, a carbonate, a phosphate, a carbamate, a sulfamate, and an acylmethylester;

R² is selected from the group consisting of alkyl, haloalkyl, and cycloalkyl, wherein the alkyl or haloalkyl is optionally substituted with one or more cycloalkykl substituents;

R⁴ is selected from the group consisting of H, halo, alkyl, alkoxy, haloalkyl, haloalkoxy and cycloalkyl, wherein alkyl or haloalkyl is optionally substituted with one or more cycloalkyl substituents, wherein alkoxy alkyl hydrogens may be optionally substituted with one or more substituents independently selected from the group consisting of alkyl and halo, and wherein R⁴ is not methyl;

R³ is selected from the group consisting of alkyl, haloalkyl, cycloalkyl, halo, and alkoxy, wherein the alkoxy may be optionally substituted with one or more substituents independently selected from the group consisting of alkyl and haloalkyl; and

R⁶ is halo.

166. The method of Claim 165, wherein the compound has a structure of Formula (XIII):

wherein D is alkyl, aryl, cycloalkyl, heterocycloalkyl, heteroalkyl, heteroaryl, heteroaralkyl, carbonylalkyl, or phosphonooxyalkyl, optionally substituted with one or more substituents selected from the group consisting of alkyl, carboxylate, heteroalkyl, monocyclic ring, bicyclic ring, and hydroxyl moieties. The method of Claim 166, wherein the compound has a structure of Formula (XIV):

wherein:

D² and D³ together with the carbon atom to which they are bonded form a cycloalkyl or cycloheteroalkyl ring, or alternatively D² and D³ are each independently selected from the group consisting of hydrogen, alkyl, and heteroalkyl,;

A, Y, and one of D² or D³ together with the atoms to which they are bonded to form a cycloheteroalkyl ring, or alternatively A is selected from the group consisting of hydrogen, phosphono, alkyl, aryl, arylalkyl, heteroalkyl, heteroaryl, and heteroarylalkyl;

X is selected from the group consisting of— ND⁴— ,— O— ,— CH₂— , and— S— ;

Y is selected from the group consisting of— O— and— ND⁴— ;

n is an integer from 1 to 5; and

D⁴ is selected from the group consisting of hydrogen, alkyl, and arylalkyl.

168. The method of Claim 167, wherein D and D are each hydrogen, X is— CH₂— , Y is— O— , A is phosphono, and n= 1.

169. The method of Claim 165, wherein R¹ is selected from the group consisting of

, and - and further wherein

is H or a pharmaceutically acceptable cation.

170. The method of Claim 169, wherein the pharmaceutically acceptable cation is selected from the group consisting of Li⁺, Na⁺, and K⁺.

171. The method of Claim 165, wherein R¹ is selected from the group consisting of

172. The method of Claim 165, wherein R is selected from the group consisting of

173. The method of Claim 165, wherein R¹

174. The method of any one of the previous claims wherein:

alkyl is selected from the group consisting of methyl, ethyl, propyl, isopropyl, butyl, isobutyl, /m-butyl, .sec-butyl, pentanyl, isopentanyl, and neopentanyl;

haloalkyl is selected from the group consisting of fluoromethyl, 1-fluoroethyl, 2-fluoroethyl, 1- fluoropropyl, 2-fluoropropyl, 3-fluoropropyl, chloromethyl, 1-chloroethyl, 2-chloroethyl, l- chloropropyl, 2-chloropropyl, 3-chloropropyl, bromomethyl, 1-bromoethyl, 2-bromoethyl, 1- bromopropyl, 2-bromopropyl, and 3-bromopropyl; and

cycloalkyl is selected from the group consisting of cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.